JPH0557242B2 - - Google Patents
Info
- Publication number
- JPH0557242B2 JPH0557242B2 JP82234891A JP23489182A JPH0557242B2 JP H0557242 B2 JPH0557242 B2 JP H0557242B2 JP 82234891 A JP82234891 A JP 82234891A JP 23489182 A JP23489182 A JP 23489182A JP H0557242 B2 JPH0557242 B2 JP H0557242B2
- Authority
- JP
- Japan
- Prior art keywords
- urea
- alkyl
- formula
- amino
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000029142 excretion Effects 0.000 claims abstract description 40
- 206010020772 Hypertension Diseases 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 16
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 229960002003 hydrochlorothiazide Drugs 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- -1 chloro, bromo, iodo Chemical group 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 17
- WNBSDCKJFDZMHT-UHFFFAOYSA-N n-(diaminomethylidene)pyrazine-2-carboxamide Chemical compound NC(N)=NC(=O)C1=CN=CC=N1 WNBSDCKJFDZMHT-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229960002155 chlorothiazide Drugs 0.000 claims description 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 6
- GTOFYYPYNNNMLP-UHFFFAOYSA-N 3-amino-n-(diaminomethylidene)pyrazine-2-carboxamide Chemical compound NC(N)=NC(=O)C1=NC=CN=C1N GTOFYYPYNNNMLP-UHFFFAOYSA-N 0.000 claims description 4
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims description 4
- 229960004064 bumetanide Drugs 0.000 claims description 4
- 229960003883 furosemide Drugs 0.000 claims description 4
- RLWRMIYXDPXIEX-UHFFFAOYSA-N muzolimine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)N1N=C(N)CC1=O RLWRMIYXDPXIEX-UHFFFAOYSA-N 0.000 claims description 4
- 229960001788 muzolimine Drugs 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- PRKWVSHZYDOZLP-UHFFFAOYSA-N 2-[(6,7-dichloro-2-methyl-1-oxo-2-phenyl-3h-inden-5-yl)oxy]acetic acid Chemical compound C1C2=CC(OCC(O)=O)=C(Cl)C(Cl)=C2C(=O)C1(C)C1=CC=CC=C1 PRKWVSHZYDOZLP-UHFFFAOYSA-N 0.000 claims description 3
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 3
- 229960000571 acetazolamide Drugs 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims description 3
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 claims description 3
- 229950005098 ethoxzolamide Drugs 0.000 claims description 3
- 229950009607 indacrinone Drugs 0.000 claims description 3
- 125000002346 iodo group Chemical group I* 0.000 claims description 3
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 claims description 3
- 229960004083 methazolamide Drugs 0.000 claims description 3
- HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002817 metolazone Drugs 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 108
- 239000004202 carbamide Substances 0.000 abstract description 55
- 208000037157 Azotemia Diseases 0.000 abstract description 8
- 208000009852 uremia Diseases 0.000 abstract description 8
- 239000002934 diuretic Substances 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 3
- 208000002296 eclampsia Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 235000013877 carbamide Nutrition 0.000 description 54
- 230000000694 effects Effects 0.000 description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 235000015424 sodium Nutrition 0.000 description 18
- 229910052708 sodium Inorganic materials 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 14
- 230000003204 osmotic effect Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 239000011591 potassium Substances 0.000 description 10
- 229910052700 potassium Inorganic materials 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000009103 reabsorption Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 6
- 241000202898 Ureaplasma Species 0.000 description 6
- 230000036765 blood level Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 230000001434 glomerular Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 5
- 229960002576 amiloride Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000003216 pyrazines Chemical class 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical class OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 210000000476 body water Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000885 nephron Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 235000021075 protein intake Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 230000010245 tubular reabsorption Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960003199 etacrynic acid Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000001452 natriuretic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000010248 tubular secretion Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WYBZTYATJKDWCI-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid;urea Chemical compound NC(N)=O.NCCC[C@H](N)C(O)=O WYBZTYATJKDWCI-WCCKRBBISA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- ZNJOCVLVYVOUGB-UHFFFAOYSA-N 1-iodooctadecane Chemical compound CCCCCCCCCCCCCCCCCCI ZNJOCVLVYVOUGB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- YGJZDMFVIMWCHL-UHFFFAOYSA-N [Na].[Mg].[K] Chemical compound [Na].[Mg].[K] YGJZDMFVIMWCHL-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 150000007658 benzothiadiazines Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020785 dietary preference Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000674 effect on sodium Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002337 osmotic diuretic agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 210000001883 posterior pituitary gland Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
æ¬çºæã¯å€å°¿å€ïŒhyperuretic agentïŒãšããŠ
æçšãªç¹å®ã®ãã©ãžã³é žèªå°äœããã³äœ¿çšããã
掻æ§æåã該ãã©ãžã³é žèªå°äœã®äžçš®ã§ããçµæ
ç©ããã³é«è¡å§çãçæ£çºäœãå°¿æ¯çããã³é¡äŒŒ
ã®çŸç ã®æ²»çæ¹æ³ã§ããã æ¬çºæã¯ãŸãå€å°¿å€ãšããŠæçšãªç¹å®ã®ãã©ãž
ã³é žèªå°äœãšçš®ã ã®å¡©åææ³å€ã®æ··åç©ããã³äœ¿
çšããã掻æ§æåã該ãã©ãžã³é žèªå°äœã®äžçš®ãš
å¡©åææ³å€ã®æ··åç©ã§ããå»è¬çµæç©ããã³é«è¡
å§çã®æ²»çæ¹æ³ã«é¢ãããã®ã§ããã ãããå å«ããåºä¹³åç©ã«ãããŠå°¿çŽ ã¯çªçŽ 代
è¬ã®äž»ãªæçµç£ç©ã§ãããå°¿çŽ ã¯ããã«æ¯æ§ã®ã¢
ã³ã¢ãã¢ããã³äºé žåççŽ ãããªã«ããã³âå°¿çŽ
ãµã€ã¯ã«ã®äžéç©ã«ããäœå ã§åæããããçŽ25
ïœã®å°¿çŽ ãïŒæ¥åœãããã®äœå ã§åæããããŸã
è èãéã€ãŠææ³ãããã å°¿çŽ ããã³ãããªãŠã ïŒå¡©åç©ïŒã¯äœã®äž»èŠãª
浞é掻æ§æåãæ§æããããã®æµžéã®åœ¹å²ã¯äºã€
ã®å°¿çŽ ããã³å¡©ã«å¯ŸããŠé¡äŒŒããŠããããéèŠãª
ç¹ã§ç°ãªã€ãŠãããå¡©åãããªãŠã ã¯ããå€å æº
ããåŸãªããã°ãªããããããªãŠã ã®ååžã¯å®è³ª
çã«è¡æŒ¿æ°Žãå å«ãã现èå€æµäœã«éå®ãããã
å°¿çŽ ã¯å€§éã«äœå ã§åæããããã®ååžã¯çŽ°èå
ããã³çŽ°èå€ã®äž¡æ¹ã§ããäžç·äœæ°Žã«ç䟡ã§ã
ããïŒã«ãªãŠã ã¯çŽ°èå€ã§ãããªãŠã ã«ãã€ãŠãš
ããã现èå 浞éã®åœ¹å²ãã¯ãããïŒ éå°ãªãããªãŠã ãäžååãªè äœçšã«ãã€ãŠæ¶
è²»ãããŸãã¯ç¶æãããå Žåãå浞éå§ã¯æžãã®
åºæ¿å¢å æµäœæ¶è²»ããã³è¡å§ã®å¢å€§ããã³ïŒãŸã
ã¯ä¹³è «ã«å°ããŠããŸãæµäœä¿æã«ãã€ãŠç¶æãã
ãã å°¿çŽ ææ³ãäœäžãããã®ã«ååãªæå·è äœçšã®
ååšäžãã®èç©ã¯ããå浞éå§é¢ä¿æ§ãæµäœèç©
ã«ãã€ãŠç¶æãããå Žåã现èå 䞊ã³ã«çŽ°èå€æµ
äœèç©ãå¢å€§ãããã®ã«ååã§ããããšãã§ã
ããå³ããç¶æ³äžã§ã¯å°¿æ¯çãçããŠããŸããå°¿
æ¯çã®çç¶äžŠã³ã«åŸŽåã«å¯ŸããŠæã説æãããã®
ã¯ãã®çŽ°èå ïŒçŽ°èå€èç©ã§ãããå°¿çŽ ããã³äœ
æ°Žã¬ãã«ã®è»œçå°¿æ¯çã®äžæã«ãããŠçç¶ã¯å¡©ä¿
æãšå®å šã«æ··åããããšãã§ãããã®å Žåå¡©åæ
æ³ãŸãã¯å€å°¿çã«åºã¥ãæ²»çã¯ããçšåºŠãŸã§ã¯äº€
æããŠçšããããšãã§ããã èšåºç¥èã®çŸåšã®äºæ ã¯å°¿çŽ ãè èã®ç³žçäœã«
ãããŠè¡æŒ¿æ°Žã§éããéããå°¿çŽ ããããã³
ã«ããå°¿çæã®éçšã«ãããŠååéæ¡æ£ãåãã
ããšãèªããŠãããå°¿çŽ ã®ååéæ¡æ£ã¯éæ¬é床
ã®å¢å€§å³ã¡ãå°¿æµåã®å¢å ã«ãã€ãŠäœäžãåŸãã å¢å€§ããéæ¬é床ã¯(1)æ²»ç芳ç¹ããèªãç¡å¹ã§
ããäœæ¶²å®¹éãå¢éãããããšã«ãã€ãŠã(2)倧é
ãéçµå£çã«æäžããããšã®å¿ èŠã®ããã«å®çšç
ã§ãªã浞éå©å°¿å€ãäŸãã°ãã³ãããŒã«ã®å©ãã§
ãŸãã¯(3)äžæãé»è§£è³ªå¹³è¡¡ãå€ããã®ã«ååãªçš
éã§æå¹ãªå¡©åææ³å€ãçšããããšã«ãã€ãŠèªçº
ããããšãã§ããã æ¬çºæã«ããã°åºä¹³åç©ã®è èãå°¿çŽ ã掻çºã«
åæ³ããã³ååžåãããã«ç³žçäœã§éããããŠ
ååéæ¡æ£ãåããããšãã§ããããšãçºèŠã
ãã ããã«ãã®äžãæ¬çºæã§å©çšããããã©ãžã³é ž
èªå°äœã¯åªäœã«å°¿çŽ ã®æŽ»æ§è è尿现管ååžåãé»
害ããããšãã§ãããã¢ããã©ã€ãã®ãã«ãªãé¡
䌌äœã®ãããªä»ã®ãã©ãžã³é žèªå°äœã¯å°¿çŽ ã®æŽ»æ§
ååžåãéèŠã«ãé»å®³ããã«å°¿çŽ ã®æŽ»æ§å°¿çŽ°ç®¡å
æ³ãåªäœã«é»å®³ããããšãçºèŠãããããããäž
ã§çŽ°èããã³çŽ°èèã®æµžéæ§èª¿ç¯äœçšã«åœ±é¿ãå
ãŒãããšãã§ãã城åãšããŠå°¿çŽ è¡æ¶²ã¬ãã«ãäœ
äžããå°¿ã®æµžéæ¿åºŠãå¢å€§ãããåŸã€ãŠãããã¯
æ²»çäžãããã®åœ¹å²ãåäžèŠããããã«æµžé調ç¯
å€ãšåŒã¶ããšãã§ããããããã®æå¹æ§ã¯è»œåºŠã®
é«è¡å§çã®åŠçããçæ£çºäœããã³ïŒãŸãã¯å°¿æ¯
çã®æªæ§ãŸãã¯é床ã®é«è¡å§çã®ç¥çµåŠççåãŸ
ã§åãŒããšã¿ãªããããçš®ã ã®å¡©åææ³å€ãšäœµçš
ãããããã®æå¹æ§ã¯è»œåºŠã®é«è¡å§çããã³èºå
èæµ®è «ã®åŠçããæªæ§ãŸãã¯é床ã®é«è¡å§çã®ç¥
çµåŠççåãŸã§åãŒããšã¿ãªãããã ã¯ã©ãŽãšç±³åœç¹èš±ç¬¬3313813å·ã¯ã«ãªãŠã ã€ãª
ã³ã®æåºãå¢å ãããã«ãããªãŠã ã€ãªã³ã®æåº
ãéžæçã«å¢å ããå©å°¿å€ããããªãŠã ææ³å€ãš
ããŠã®ïŒâã¢ããâïŒïŒïŒâãžçœ®æâãã©ãžãã€
ã«ã°ã¢ããžã³ããã³ãããã®çšéãèšèŒããŠã
ãã V.Gen.Ppysiol.第68(1)å·»ã第43ã63é ïŒ1976
幎ïŒã®ããã¹çã¯åé¢ããã«ãšã«ã®ç®èããã³è
質èèã«ãããã«ããªã³éæ¬ã«ã¢ããã©ã€ããã
ã³ãã®é¡äŒŒäœã®ããã€ãã®å¹æãèšèŒããŠããã ããããªãããããã®æç®ã¯ãã©ãžã³é žèªå°äœ
ã®å€å°¿å€æŽ»æ§ã瀺åããŠãããã該èªå°äœã該åŒ
äŸã«èšèŒããèŠä»¶ã«åŸã€ãŠæçšã§ããååãªå¡©å
ææ³ããã³æã«ãªãŠã ææ³äœçšãæããªãããšã
ãããããã®æ¹æ³ã®äžèšåŒäŸãé«è¡å§çãçæ£çº
äœãå°¿æ¯çãªã©ã®æ²»çã«å¯ŸããŠæ¬çºæã§å©çšãã
ãç¹å®ã®ãã©ãžã³é žèªå°äœå€å°¿å€ã®äœ¿çšã瀺åã
ãŠããªãã æ¬çºæã«ããã°å»è¬çã«äœ¿çšãåŸãæ äœããã³
æ²»çäžæå¹éã®åŒïŒ ãåŒäž ã¯ïŒ¯ãŸãã¯NHã§ããã ã¯OHãNHCONR4R5ãŸãã¯ïŒ®ïŒïŒ£ïŒNR4
R5ïŒ2 ã§ãããïŒåŒäžR4ããã³R5ã¯åã æ°ŽçŽ ãçŽéãŸã
ã¯åæéC1-10ã¢ã«ãã«ãã¢ãªãŒã«C1-4ã¢ã«ãã«ã
眮æåºããã«ãªããã¯ãããããã¢ããšãŒããŸã
ã¯çŽéãŸãã¯åæéã§ããã¢ããŸãã¯çœ®æã¢ãªãŒ
ã«C1-4ã¢ã«ãã«ãããªã矀ããéžæããããïŒ R1ããã³R2ã¯åã æ°ŽçŽ ãã¢ããããã³çœ®æåº
ãçŽéãŸãã¯åæéC1-10ã¢ã«ãã«ãŸãã¯C3-8ã·
ã¯ãã¢ã«ãã«ã§ããã¢ããŸãã¯ãžçœ®æã¢ãããã
ãªã矀ããéžæããããäœãR1ããã³R2ã¯äž¡æ¹
ãã¢ãããŸãã¯çœ®æã¢ããã§ããããšãã§ããªã
ããã³ R3ã¯æ°ŽçŽ ããã«ãªããã¯ãããããã¢ãŸãã¯
ãšãŒãã§ãããã ãæããååç©ããã³ãã®å»è¬çã«äœ¿çšãåŸãå¡©
ãããªãå€å°¿å€çšéã®å»è¬çµæç©ãæäŸããã æ¬çºæã«ããã°ããã«å»è¬çã«äœ¿çšãåŸãæ äœ
ããã³æ²»çäžæå¹éã® (a) åŒã®ååç©ããã³ (b) ãšã¿ã¯ãªããã¯ã¢ã·ãããããã»ããããã¡
ã¿ãããã ãŸãªãã³ãã¯ãããã¢ãžãããã³ã
ã€ããã¯ãããã¢ãžããå å«ãããã³ãŸãã¢ãž
ã¢ãžã³ãã¯ããã¿ãªãã³ãããã¿ãŸã³ãã¡ãã
ãŸã³ãã€ã³ãã¯ãªãã³ãã¢ã»ã¿ãŸãŒã«ã¢ããã
ãšããã·ãŸãŒã«ã¢ããããã³ã¡ã¿ãŸãŒã«ã¢ãã
ãããªã矀ããéžæãããå¡©åææ³å€ ã®æ··åç©ãããªãé«è¡å§çããã³æµ®è «ã®æ²»çã«å¯Ÿ
ããå»è¬çµæç©ãæäŸããã æ¬çºæã®å¥œé©ãªååç©ã¯ïŒ¹ããŸãã¯NHã§ã
ããR1ããã³R2ã®äžã€ãæ°ŽçŽ ãŸãã¯ã¢ããã§ã
ããä»ãæ°ŽçŽ ã§ããããã³R3ãæ°ŽçŽ ã§ããåŒ
ã®ååç©ã§ãããæ¬çºæã®å¥œé©ãªæ··åç©ã¯åŒã®
奜é©ãªååç©ã䜿çšããå¡©åææ³å€ããã€ããã¯
ãããã¢ãžãã§ããååç©ã§ããã æ¬çºæã®ç¹ã«å¥œé©ãªååç©ã¯æ¬¡ã®ãã®ã§ããã ãã©ãžãã€ã«ã°ã¢ããžã³ã ïŒâã¢ãããã©ãžãã€ã«ã°ã¢ããžã³ åŒååç©ã¯ç¡æ©ãŸãã¯ææ©é žããèªå°ããã
å¡©ã®åœ¢æ ã§çšããããšãã§ããã次ã®ãã®ããã
ãå¡©ã«å å«ãããïŒé ¢é žå¡©ãã¢ãžãã³é žå¡©ãã¢ã«
ã®ãã³é žå¡©ãã¢ã¹ãã©ã®ã³é žå¡©ãå®æ¯éŠé žå¡©ãã
ã³ãŒã³ã¹ã«ãã³é žå¡©ãéç¡«é žå¡©ãé ªé žå¡©ãã¯ãšã³
é žå¡©ãã·ãšãŠããŠé žå¡©ãã«ã³ãã«ã¹ã«ãããŒãã
ã·ã¯ããã³ã¿ã³ããããªããŒãããžã°ã«ã³ããŒ
ããããã·ã«ãµã«ããšãŒãããšã¿ã³ã¹ã«ãããŒ
ããããã«é žå¡©ãã°ã«ã³ããã¿ããšãŒãããããµ
ã³é žå¡©ãå¡©é žå¡©ãèåæ°ŽçŽ é žå¡©ããšãŠåæ°ŽçŽ é ž
å¡©ãïŒâããããã·ãšã¿ã³ã¹ã«ãããŒããä¹³é ž
å¡©ããã¬ã€ã³é žå¡©ãã¡ã¿ã³ã¹ã«ãã³é žå¡©ãïŒâã
ãã¿ã¬ã³ã¹ã«ãã³é žå¡©ããã³ãã³é žå¡©ãã·ãŠãŠé ž
å¡©ããã¢ãšãŒãããã¯ãã³é žå¡©ãéç¡«é žå¡©ãïŒâ
ããšãã«ããããªã³é žå¡©ããã¯ãªã³é žå¡©ãããã«
é žå¡©ãããããªã³é žå¡©ãã³ãã¯é žå¡©ãé ç³é žå¡©ã
ããªã·ã¢ã³é žå¡©ããã·ã¬ãŒãããã³ãŠã³ãã«ã³é ž
å¡©ããŸãå¡©åºæ§çªçŽ âå«æåºãå¡©åãèåããã³
ãšãŠåã¡ãã«ããšãã«ããããã«ããã³ããã«ã®
ãããªäœçŽã¢ã«ãã«ãã©ã€ãããžã¡ãã«ããžãšã
ã«ããžããã«ã®ãããªãžã¢ã«ãã«ã¹ã«ããšãŒãã
ãã³ãžã¢ãã«ã¹ã«ããšãŒããå¡©åãèåããã³ãš
ãŠåããã·ã«ãã©ãŠãªã«ãããªã¹ãã«ããã³ã¹ã
ã¢ãªã«ã®ãããªé·éãã©ã€ãããã³ãžã«ããã³ã
ãšããã«ãããã€ãã®ãããªã¢ã©ã«ãã«ãã©ã€ã
ãªã©ã®è¬å€ã§ç¬¬åçŽåããããšãã§ãããæ°ŽãŸã
ã¯æ²¹æº¶æ§ãŸãã¯åæ£æ§çæç©ãããã«ãã€ãŠåŸã
ããã æ¬çºæã®ãã©ãžã³é žèªå°äœã¯é«åºŠã®å€å°¿äœçšã
æããããããã¯é«è¡å§çã®æ²»çã«æçšã§ããã
äžè¬ã«ãããã¯äžæããå°¿çŽ ã¬ãã«ãæãããªã
ãªãæ§ã ãªçç¶ã«å¯ŸããŠç€ºãããããã®ã«ããŽãª
ãŒã®äžã«çæ£çºäœããã³å°¿æ¯çã®ãããªçŸç ãå
å«ãããã æ¬çºæã®ãã©ãžã³é žèªå°äœããã³å¡©åææ³å€æ··
åç©ã¯é«åºŠã®å€å°¿ããã³å¡©åææ³ïŒå©å°¿äœçšãæ
ãããåŸã€ãŠãããã¯é«è¡å§çããã³æµ®è «ã®æ²»ç
ã«æçšã§ããã ãããã®ç®çã«å¯ŸããŠæ¬çºæã®ååç©ããã³æ··
åç©ã¯éäŸç¡æ¯æ§ã®å»è¬çã«äœ¿çšãåŸãæ äœãè£
å©è¬ããã³è³Šåœ¢å€ãå«æããçšéåäœåŠæ¹ã§çµå£
çã«ãå±æçã«ãéçµå£çã«ãåžå ¥ã¹ãã¬ãŒã«ã
ã€ãŠãŸãã¯çŽè žçã«æäžããããšãã§ãããæ¬æ
现æžã§çšããããéçµå£ãªãçšèªã¯ç®äžæ³šå°ãé
èå ãçèå ãèžéªšå 泚å°ãŸãã¯æ³šå ¥æè¡ãå å«
ãããããŠã¹ãã©ããããŠããã€ãããã³ãªã©ã®
ãããªæž©è¡åç©ã®æ²»çã®ä»ã«ãæ¬çºæã®ååç©ã¯
ããã®æ²»çã«æå¹ã§ããã 掻æ§æåãå«æããå»è¬çµæç©ã¯äŸãã°é å€ã
ãããŒãå€ãããŒã³ãžå€ãæ°Žæ§ãŸãã¯æ²¹æ§æžæ¿æ¶²
å€ãåæ£æ§æ£å€ãŸãã¯é¡ç²å€ãä¹³å€ç¡¬ãŸãã¯è»ã«
ãã»ã«å€ãã·ãããå€ãŸãã¯ãšãªãã·ã«å€ã®çµå£
çšã«é©åœãªåœ¢æ ã«ããããšãã§ãããçµå£çšã«äŒ
å³ãããçµæç©ã¯å»è¬çµæç©ã®è£œé ã«å¯ŸããŠåœè©²
æè¡ã«å ¬ç¥ã®ããããæ¹æ³ã«åŸã€ãŠèª¿è£œããããš
ãã§ãããããçµæç©ã¯å»è¬çã«ãšã¬ã¬ã³ããªã
ããŠçŸå³ãªè£œå€ãæäŸããããã«çå³å€ãéŠå³
å€ãçè²å€ããã³é²è å€ãããªã矀ããéžæãã
ãïŒçš®ãŸãã¯ãã以äžã®è¬å€ãå«æããããšãã§
ãããé å€ã¯é å€ã®è£œé ã«é©åœãªç¡æ¯æ§ã®å»è¬ç
ã«äœ¿çšãåŸã賊圢å€ãšæ··åãã掻æ§æåãå«æã
ãããããã®è³Šåœ¢å€ã¯äŸãã°çé žã«ã«ã·ãŠã ãç
é žãããªãŠã ãä¹³ç³ããªã³é žã«ã«ã·ãŠã ãŸãã¯ãª
ã³é žãããªãŠã ã®ãããªäžæŽ»æ§åžéå€ãé¡ç²åã
ãã³åŽ©å£å€ãäŸãã°ã³ãŒã³ã¹ã¿ãŒããŸãã¯ã¢ã«ã®
ã³é žãçµåå€ãäŸãã°ã¹ã¿ãŒãããŒã©ãã³ãŸãã¯
ã¢ã©ãã¢ãŽã ããã³æœ€æ»å€ãäŸãã°ã¹ãã¢ãªã³é ž
ãã°ãã·ãŠã ãã¹ãã¢ãªã³é žãŸãã¯ã¿ã«ã¯ã§ãã
ããšãã§ãããé å€ã¯æªè¢«èŠã§ããããšãã§ãã
ããã¯èè žç®¡ã®åŽ©å£ããã³åžåãé ãããããã«
ãã€ãŠé·æéã«ããã€ãŠç¶æãããäœçšãæäŸã
ãããã«å ¬ç¥ã®æè¡ã«ãã€ãŠè¢«èŠããããšãã§ã
ããäŸãã°ã°ãªã»ãªã«ã¢ãã¹ãã¢ã¬ãŒããŸãã¯ã°
ãªã»ãªã«ãžã¹ãã¢ã¬ãŒãã®ãããªæéé 延ç©è³ªã
åç¬ã§ãŸãã¯ã¯ãã¯ã¹ãšãšãã«äœ¿çšããããšãã§
ããã çµå£çšã®åŠæ¹ããŸã掻æ§æåãäžæŽ»æ§åºäœåžé
å€ãäŸãã°çé žã«ã«ã·ãŠã ããªã³é žã«ã«ã·ãŠã ãŸ
ãã¯ã«ãªãªã³ãšæ··åãã硬ãŒã©ãã³ã«ãã»ã«å€ãš
ããŠãŸãã¯æŽ»æ§æåãæ°ŽãŸãã¯æ²¹åªè³ªãäŸãã°èœ
è±çæ²¹ãããŒããæ²¹ãæµåãã©ãã€ã³ãŸãã¯ãªãª
ãŒãæ²¹ãšæ··åããè»ãŒã©ãã³ã«ãã»ã«å€ãšããŠäž
ããããšãã§ããã æ°Žæ§æžæ¿æ¶²å€ã¯æ°Žæ§æžæ¿æ¶²ã®è£œé ã«é©åœãªè³Šåœ¢
å€ãšæ··åãã掻æ§ç©è³ªãå«æãããããã賊圢å€
ã¯æ²æ®¿é²æ¢å€ãäŸãã°ãããªãŠã ã«ã«ããã·ã¡ã
ã«ã»ã«ããŒã¹ãã¡ãã«ã»ã«ããŒã¹ãããããã·ã
ããã«ã¡ãã«ã»ã«ããŒã¹ãã¢ã«ã®ã³é žãããªãŠ
ã ãããªããã«ãããªãã³ããã©ã¬ã³ããŽã ãã
ã³ã¢ã©ãã¢ãŽã ã§ãããåæ£å€ãŸãã¯æ¹¿æœ€å€ã¯å€©
ç¶ã®ãã¹ãã¢ãããäŸãã°ã¬ã·ãã³ãŸãã¯ã¢ã«ã
ã¬ã³ãªããµã€ããšèèªé žãšã®çž®åçæç©ãäŸãã°
ããªãªãã·ãšãã¬ã³ã¹ãã¢ã¬ãŒããŸãã¯ãšãã¬ã³
ãªããµã€ããšé·éèèªæã¢ã«ã³ãŒã«ãšã®çž®åçæ
ç©ãäŸãã°ããã¿ãã«ãšãã¬ã³ãªãã·ã»ã¿ããŒã«
ãŸãã¯ããªãªãã·ãšãã¬ã³ãœã«ãããŒã«ã¢ããªã¬
ãšãŒãã®ãããªèèªé žãšããã·ããŒã«ããèªå°ã
ããéšåãšã¹ãã«ãšãšãã¬ã³ãªããµã€ããšã®çž®å
çæç©ãŸãã¯ãšãã¬ã³ãªããµã€ããšèèªé žããã³
ããã·ããŒã«ç¡æ°Žç©ããèªå°ãããéšåãšã¹ãã«
ãšã®çž®åçæç©ãäŸãã°ããªãªãã·ãšãã¬ã³ãœã«
ãã¿ã³ã¢ããªã¬ãšãŒãã§ããã該氎æ§æžæ¿æ¶²ããŸ
ãïŒçš®ãŸãã¯ãã以äžã®é²è å€ãäŸãã°ãšãã«ãŸ
ãã¯ïœâãããã«ïœâããããã·ãã³ãŸãšãŒãã
ïŒçš®ãŸãã¯ãã以äžã®çè²å€ãïŒçš®ãŸãã¯ãã以
äžã®éŠå³å€ããã³ã¹ã¯ããŒã¹ãŸãã¯ãµãã«ãªã³ã®
ãããªïŒçš®ãŸãã¯ãã以äžã®çå³å€ãå«æããã
ãšãã§ããã æ²¹æ§æžæ¿æ¶²å€ã¯æŽ»æ§æåãæ€ç©æ²¹ãäŸãã°èœè±
çæ²¹ããªãªãŒãæ²¹ããŽãæ²¹ãŸãã¯ã€ã·æ²¹äžã«ãŸã
ã¯æµåãã©ãã€ã³ã®ãããªé±ç©æ²¹äžã«æžæ¿ããã
ããšã«ãã€ãŠåŠæ¹ããããšãã§ãããæ²¹æ§æžæ¿æ¶²
å€ã¯æ¿ååå€äŸãã°ããããŠãåºåœ¢ãã©ãã€ã³ãŸ
ãã¯ã»ãã«ã¢ã«ã³ãŒã«ãå«æããããšãã§ããã
äžèšã§ç€ºãããããªçå³å€ããã³éŠå³å€ãçŸå³ãª
çµå£è£œå€ãæäŸããããã«æ·»å ããããšãã§ã
ãããããã®çµæç©ã¯ã¢ã¹ã³ã«ãã³é žã®ãããªæ
é žåå€ã®æ·»å ã«ãã€ãŠä¿åããããšãã§ããã æ°Žã®æ·»å ã«ãã€ãŠæ°Žæ§æžæ¿æ¶²ã®èª¿è£œã«é©åœãªå
æ£å€ããã³é¡ç²å€ã¯åæ£å€ãŸãã¯æ¹¿æœ€å€ãæ²æ®¿é²
æ¢å€ããã³ïŒçš®ãŸãã¯ãã以äžã®é²è å€ãšæ··åã
ã掻æ§æåãæäŸãããé©åœãªåæ£ãŸãã¯æ¹¿æœ€å€
ããã³æ²æ®¿é²æ¢å€ã¯äžèšã§æ¢ã«èšåãããã®ã«ã
ã€ãŠäŸç€ºããããããã«è³Šåœ¢å€ãäŸãã°çå³å€ã
éŠå³å€ããã³çè²å€ããŸãååšãããããšãã§ã
ãã æ¬çºæã®å»è¬çµæç©ã¯ãŸãæ°Žäžæ²¹åãšãã«ãžãš
ã³ã®åœ¢æ ã«ããããšãã§ãããæ²¹çžã¯æ€ç©æ²¹ãäŸ
ãã°ãªãªãŒãæ²¹ãŸãã¯èœè±çæ²¹ãŸãã¯é±ç©æ²¹ãäŸ
ãã°æµåãã©ãã€ã³ãŸãã¯ãããã®æ··åç©ã§ãã
ããšãã§ãããé©åœãªä¹³åå€ã¯å€©ç¶ãŽã ãäŸãã°
ã¢ã©ãã¢ãŽã ãŸãã¯ãã©ã¬ã³ããŽã ã倩ç¶ãã¹ã
ã¢ãããäŸãã°å€§è±æ²¹ã¬ã·ãã³ããã³èèªé žãã
ã³ããã·ããŒã«ç¡æ°Žç©ããèªå°ããããšã¹ãã«ãŸ
ãã¯éšåãšã¹ãã«ãäŸãã°ãœã«ãã¿ã³ã¢ããªã¬ãš
ãŒãããã³è©²éšåãšã¹ãã«ãšãšãã¬ã³ãªããµã€ã
ã®çž®åçæç©ãäŸãã°ããªãªãã·ãšãã¬ã³ãœã«ã
ã¿ã³ã¢ããªã¬ãšãŒãã§ããããšãã§ãããä¹³å€ã
ãŸãçå³å€ããã³éŠå³å€ãå«æããããšãã§ã
ãã ã·ãããå€ããã³ãšãªãã·ã«å€ã¯çå³å€ãäŸã
ã°ã°ãªã»ããŒã«ããœã«ãããŒã«ãŸãã¯ã¹ã¯ããŒã¹
ã§åŠæ¹ããããšãã§ããããããåŠæ¹ã¯ãŸãä¿è·
å€ãé²è å€ããã³éŠå³å€ããã³çè²å€ãå«æãã
ããšãã§ãããå»è¬çµæç©ã¯æ» è泚å°çšè£œå€ã®åœ¢
æ ã«ãäŸãã°æ» è泚å°çšæ°Žæ§ãŸãã¯æ²¹æ§æžæ¿æ¶²ãš
ããŠããããšãã§ããããã®æžæ¿æ¶²ã¯äžèšã§èšå
ããé©åœãªåæ£ãŸãã¯æ¹¿æœ€å€ããã³æ²æ®¿é²æ¢å€ã
çšããŠå ¬ç¥ã®æè¡ã«åŸã€ãŠåŠæ¹ããããšãã§ã
ããæ» è泚å°çšè£œå€ããŸãç¡æ¯æ§ã®éçµå£çã«äœ¿
çšãåŸãåžéå€ãŸãã¯æº¶åªäžæ» è泚å°çšæ°Žæº¶æ¶²ãŸ
ãã¯æžæ¿æ¶²ãäŸãã°ïŒïŒïŒâãã¿ã³ãžãªãŒã«äžæº¶
液ãšããŠããããšãã§ããã䜿çšããããšãã§ã
ã䜿çšãåŸã賊圢å€ããã³æº¶åªã«ã¯æ°Žããªã³ã²ã«
液ããã³å¡©åãããªãŠã ç匵溶液ããããããã«
æ» èãäžæ®çºæ²¹ã溶åªãŸãã¯æžæ¿åªè³ªãšããŠéäŸ
䜿çšãããããã®ç®çã«å¯ŸããŠåæã¢ããŸãã¯ãž
ã°ãªã»ã©ã€ããå å«ããããããç¡åºæ¿äžæ®çºæ²¹
ã䜿çšããããšãã§ãããããã«ãªã¬ã€ã³é žã®ã
ããªèèªé žã¯æ³šå°çšå€ã®èª¿è£œã«äœ¿çšãèŠåºããã æ¬çºæã®ååç©ããã³æ··åç©ã¯ãŸãè¬å€ã®çŽè ž
æäžãšããŠåè¬ã®åœ¢æ ã§æäžããããšãã§ããã
ãããã®çµæç©ã¯è¬å€ãéåžžã®æž©åºŠã§åºäœã§ãã
ãçŽè žæž©åºŠã§æ¶²äœã§ããé©åœãªç¡åºæ¿è³Šåœ¢å€ãšæ··
åããããšã«ãã€ãŠèª¿è£œããããšãã§ããããæ
çŽè žå ã§è解ããŠè¬å€ãæŸåºããããããææã¯
ã³ã³ã¢ãã¿ãŒããã³ããªãšãã¬ã³ã°ãªã³ãŒã«ã§ã
ãã å±æçšãšããŠæŽ»æ§æåãå«æããã¯ãªãŒã å€ã
è»èããŒãªãŒå€ã液å€ãŸãã¯æžæ¿æ¶²å€ã䜿çšã
ãã åŒã®ååç©ã«å¯ŸããŠïŒæ¥åœãçŽ25ã750mgã®
çšéã¬ãã«ãäžèšã§ç€ºããçç¶ã®æ²»çã«æçšã§ã
ããå ·äœçã«ã¯é«è¡å§çã¯ïŒæ¥åœãäœéïŒKgã«ã€
ãååç©çŽ0.5ã15mgæäžããããšã«ãã€ãŠæå¹
ã«æ²»çããããæå©ã«ã¯äœéïŒKgåœãçŽïŒã15mg
ããã³ç¹ã«ïŒKgåœãçŽïŒã10mgæ¥çšéã極ããŠæ
å¹ãªçµæãçããã æ¬çºæã®æ··åç©ã®å¡©åææ³å€ãšããŠã®çšéã¬ã
ã«ã¯äžè¬ã«å¥ã ã®æ²»çãšããŠãããã®è¬å€ã«å¯Ÿã
ã確ç«ããçšéã«ããã äžåã®çšé圢æ ã補é ããããã«æ äœææãšæ··
åããããšãã§ãã掻æ§æåéã¯æ²»çããã宿䞻
ããã³ç¹å®ã®æäžæ¹æ³ã«äŸåããŠå€åãããäŸã
ã°ããã®çµå£æäžã«å¯ŸããŠäŒå³ãããåŠæ¹ã¯å šçµ
æç©ã®çŽïŒã95ïŒ ãå€åããããšãã§ããæ äœæ
æã®é©åœããã³éåžžéãšååãã掻æ§è¬å€25ã
750mgãå«æããããšãã§ãããçšéåäœåœ¢æ ã¯
äžè¬ã«æŽ»æ§æåçŽ25ã500mgãå«æããããšãã§
ããã ããããªããããããç¹å®æ£è ã«å¯ŸããŠç¹å®ã®
æçšéã¬ãã«ã¯äœ¿çšãããç¹å®ååç©ã®æŽ»æ§ã幎
什ãäœéãå šèº«ã®å¥åº·ãæ§ãé£é€ãæäžæéãæ
äžçµè·¯ãææ³é床ãè¬å€ã®äœµçšããã³æ²»çããç¹
å®çŸç ã®éããå å«ããæ§ã ãªå åã«äŸåããã æ¬çºæã«ããã°ããã«æ²»çäžæå¹ãªéã®åŒïŒ ïŒåŒäžïŒ¹ããR1ãR2ããã³R3ã¯äžèšãšåäž
ã®æå³ãæãããïŒ ãæããååç©ãæ²»çãå¿ èŠãšãã宿䞻ã«æäžã
ãããšãããªãé«è¡å§çã®æ²»çæ¹æ³ãæäŸãã
ãã ãªãããã«ãŸãæ¬çºæã«ããã°ãæ²»çäžæå¹ãª
éã®åŒïŒ ïŒåŒäžïŒ¹ããR1ãR2ããã³R3ã¯äžèšãšåäž
ã®æå³ãæãããïŒ ãæããååç©ãæ²»çãå¿ èŠãšããŠãã宿䞻ã«æ
äžããããšãããªãå€å°¿æ¯çç¶ã®æ²»çæ¹æ³ãæäŸ
ãããã ããã«æ¬çºæã«ããã° (a) åŒ ïŒåŒäžïŒ¹ããR1ãR2ããã³R3ã¯äžèšãšå
äžã®æå³ãæãããïŒ ãæããååç©ããã³ (b) å®è³ªçã«ãšã¿ã¯ãªããã¯ã¢ã·ãããããã»ã
ãããã¡ã¿ãããã ãŸãªãã³ãã¯ãããã¢ãžã
ããã³ãã€ããã¯ãããã¢ãžããå å«ãããã³
ãŸãã¢ãžã¢ãžã³ãããªã矀ããéžæãããå¡©å
ææ³å€ ã®æ··åç©ã®æ²»çäžæå¹ãªéãæ²»çãå¿ èŠãšããŠã
ã宿䞻ã«æäžããããšãããªãé«è¡å§çã®æ²»çæ¹
æ³ãæäŸãããã ãªãããã«ãŸãæ¬çºæã«ããã° (a) åŒ ïŒåŒäžïŒ¹ããR1ãR2ããã³R3ã¯äžèšãšå
äžã®æå³ãæãããïŒ ãæããååç©ããã³ (b) å®è³ªçã«ãšã¿ã¯ãªããã¯ã¢ã·ãããããã»ã
ãããã¡ã¿ãããã ãŸãªãã³ãã¯ãããã¢ãžã
ããã³ãã€ããã¯ãããã¢ãžããå å«ãããã³
ãŸãã¢ãžã¢ãžã³ãã¯ããã¿ãªãã³ãããã¿ãŸ
ã³ãã¡ãã©ãŸã³ãã€ã³ãã¯ãªãã³ãã¢ã»ã¿ãŸãŒ
ã«ã¢ããããšããã·ãŸãŒã«ã¢ããããã³ã¡ã¿ãŸ
ãŒã«ã¢ãããããªã矀ããéžæãããå¡©åææ³
å€ ã®æ··åç©ã®æ²»çäžæå¹ãªéãæ²»çãå¿ èŠãšããŠã
ã宿䞻ã«æäžããããšãããªãæµ®è «ã®æ²»çæ¹æ³ã
æäŸãããã åŒã®ååç©ã¯ãããªãŠã ãã¯ãã©ã€ãããã³
ã«ãªãŠã ã®å¢å€§ããæåºãå å«ããæçšéé¢é£æ¹
æ³ã§å°¿çŽ ãããååžåãé»å®³ããããããã®å¹æ
ã¯å°¿æµåºãšã¯ç¡é¢ä¿ã§ãããååéæ¡æ£ãæå°å
ããæ¡ä»¶äžã§å°¿çŽ ã¯ãªã¢ã©ã³ã¹ãã»ãŒç³žçäœé
çã«å¢å€§ãããã è è现管ã®ç®¡è ãžã®å°¿çŽ ã®åæ³ãé»å®³ãããã
ã®å€åãåŸãèœåããã©ãžã³é žèªå°äœã«ãããã
ãã¯æ¬çºæã®ãã©ãžãã€ã«ã°ã¢ããžã³ã§æå°ã§ã
ãããã«ããã¢ã³ã¹ã§ãã®å¹æã¯æçœã§ã¯ãªã
ããã¢ããã©ã€ãã®ãã«ãªãé¡äŒŒäœã¯éæ¡æ£ãæ
å°ã®æã§ãããå°¿çŽ åæ³ããã³æµäœæåºãã»ãšã
ã©å®å šã«é»å®³ãããã¹ãããâãããŒå®éšã«ãã
ãŠæŽ»æ§ååžåããã³åæ³ã®é»å®³ã説æããããšã
ã§ããã æ¬çºæã§å©çšãããåŒã®ååç©ã¯çµå£äžŠã³ã«
éçµå£æäžã§æŽ»æ§ã§ãããïŒâã¢ãããã©ãžãã€
ã«ã°ã¢ããžã³ãå³åº§ã«æãæå¹ã§ãããããã©ãž
ãã€ã«ã°ã¢ããžã³å¹æããã³è¡æ¶²ã¬ãã«ã¯æ倧å¹
æã«å¯ŸããŠæããè¿œå æéãå¿ èŠãšããã æ¢ã«ç€ºããéããæ¬çºæã§å©çšãããåŒã®å
åç©ã¯åœç¶æµžé調ç¯å€ãšåŒã¶ããšãã§ããã浞é
床調ç¯ã¯é 次æ°çš®ã®çžäºã«é¢ä¿ããå åãå å«ã
ãã ãããªãŠã ãã¯ãã©ã€ãããã³éçé žå¡©ã€ãªã³
ã®åèšãšããŠå¡©ã¯ããã®çŽ°èå€æ°Ž300ããªãªã¹ã¢
ã«ïŒïŒ¬ã®çŽ93ïŒ ãäŸçµŠãããå°¿çŽ ã¯æšæºçã«ã¯ã
ãã®æµžéåã®çŽ1.3ïŒ ãäŸçµŠãããä»ã®æåã®1.8
ïŒ ã°ã«ã³ãŒã¹ã ãã浞é床調ç¯ã®å åã§ããã åŸã€ãŠç匵æ§ãç¶æããããã®æ°Žéã®æµžé床調
ç¯ã¯æžã«ããããã³æ°Žã®ååžåã調ç¯ããããã
ã³ã®æãæ«ç«¯éšåã§ã®æå©å°¿ãã«ã¢ã³ã®äœçšã«ã
ãã塩調ç¯ã«å¯ŸããŠé£æãããããè èã¯ãããª
ãŠã ä¿åãæ倧ã«ããããã«äœãããŠããããã«
èŠããã塩調ç¯ãã«ã¢ã³ã«å¯Ÿããç 究ãç¶ããŠã
ãããè èã®å ¬ç¥ã®â掻æ§âãããªãŠã ååžåæ©
æ§ã ãããæ°ŽçŽ ã€ãªã³ã®æå¹æ§ããã³ïŒãŸãã¯ã
ããã³ã暪åããããªãŠã ãšã®äº€æã®ããã®ã«ãª
ãŠã ã®ã¢ã«ãã¹ããã³èª¿ç¯æå¹æ§ãå å«ãããã
ãååžåããããªãŠã å©å°¿ãŸãã¯å¡©åææ³å©å°¿å€
ã®äœçšã«ãã€ãŠæžå°ããªããªãã°ããããªãŠã ã
æ°Žã®æåºãå¢å€§ããããã®æ段ãšã¯ãã€ãã«ãªã
ãªãã ããåç平衡æ©æ§ããããããããªãŠã ãã³ã
ãŸãã¯çŽ°èèã«å ±éã®ãããªãŠã âã«ãªãŠã âã
ã°ãã·ãŠã äŸåã®ATPâaseæ©æ§ã¯äž»ãšããŠçŽ°è
å€ç©ºéãžã®æµäœéãŸãã¯å šçŽ°èããã³çŽ°èå€å®¹é
ã®çŽ25ïŒ ã§ãããªãŠã ã®æµžé調ç¯å¹æãäžããã
ãã«åããåŸã€ãŠãããªãŠã ä¿æã«ããã極ããŠ
å°éã®å¢å ã¯çŽ°èå€å®¹éãæ¡åŒµããããšãã§ãã
åŸã€ãŠçŽ°è容éãå®è³ªçã«æããåãããšãªãè¡
å§ããã³ç³žçäœéçãå¢å ããããšãã§ããã ä»æ¹ãäžåäœåŸèã®çŽ°èã«ããæžã®æµžé床調ç¯
ã¯å°¿çŽ æ¿åºŠã«ããææã§ã¯ãªããAPHãæ°Žååž
åã«åœ±é¿ããããã«è èã«ãã€ãŠå°¿çŽ éæ¡æ£ãå€
åãããéã«æšæºçã«ã¯ïŒæ¥åœãå°¿çŽ çŽ25ïœãæ
åºããããã®è èã®äžã§ç©è³ªã¯æ°Žã®æåºã®äž»èŠãª
浞é調ç¯ãšããŠåãã å°¿çŽ ã®è¡æŒ¿æ¿åºŠã¯äž¡æ¹ã®èçœè³ªæåéã«ãã€ãŠ
ããã³ç³žçäœã«ããéãããéã®äžéšã®è 现管
ååžåã«ãã€ãŠåœ±é¿ããããšãã§ãããåŸã€ãŠé«
èçœè³ªã®é£é€ã¯å°¿çŽ ããã³æ°Žã®æåºã®äž¡æ¹ãå¢å
ãããäœèçœè³ªæåéãŸãã¯äœäžãã糞çäœé
çã¯å°¿çŽ ããã³æµäœæåºéãæžå°ãããè¿äŒŒãšã
ãŠãã糞çäœéçãæšæºã®ååã«äœäžãããªã
ã°ãå°¿çŽ ã®è¡æŒ¿æ°Žæ¿åºŠã¯äžå®ã®èçœè³ªæåéã§ïŒ
åã«ãªãããã®çµæã¯çŽ°èå 容é䞊ã³ã«çŽ°èå€ã
45ïŒ25ãŸãã¯1.8ã®æ¯çã§æ¡åŒµããäžå®ã®æµžéå§
ããšãã°é¢ä¿æ§ã¯äºç©ºéã«ååšãããäºç©ºéã®ã
ã®éèŠãªå·®ç°ã«å¯Ÿããçç±ã¯ãããªãŠã ãå®è³ªç
ã«çŽ°èå€ç©ºéã«éå®ãããäžæ¹ãå°¿çŽ ã¯å¹Ÿååç
ã«äœæ°Žäžã«åé ãããããšã§ãããåŸã€ãŠå°¿çŽ è¡
挿æ¿åºŠãæ£åžžã®äºåã§ããã现èå€å®¹éãæ¡åŒµã
ãæ£è ã¯å°¿çŽ ã¬ãã«ãæ£åžžã§ããå Žåããããã«
å€éã®æ¡åŒµããå šå®¹éãéæ¬ãããå¢å ããå šé
ããããªãéèŠã§ããããšãã§ããããšã¯å¢å ã
ãâ现èå âæµäœã现èããããã®èããããã®
æ§é ã®åºç»åïŒcompartmentalizationïŒå ã«å
é ããããšããããšã§ããã å¡©ã®ããã«å°¿çŽ ã¯ããç匵æ§ãç¶æããããã«
ååãªæ°Žãšãšãã«æäžããããªãã°æ£åžžãªè¢«æ€è
ã«æ¿ããæ¯æ§ã¯ãªããããããªããé¡èãªå€å°¿æ¯
çã«å¯Ÿãã調æŽã¯äœã®æµäœãäœãããªãŠã è¡çã
äœã«ãªãŠã è¡çã®ã²ã©ãäžå¹³è¡¡ãå å«ããããã«
äºæãããã°ã¢ããžã³å¡©åºã®æ¯æ§ã«äŒŒãŠããç©è³ª
ã®ä¿æã¯å°¿æ¯çã®å šäœã§ãããå€åãåŸãèšåºå
ã«å¯äžãããšèããããšãã§ããã åè¿°ã®å°¿çŽ ããã³å¡©ãšã®é¢ä¿æ§ãèæ ®ããŠãå¡©
åææ³å©å°¿æ²»çãå€å°¿æ¯çã®ãªãæµäœä¿æã®åå
ãªã³ã³ãããŒã«ã§ãããšããããšã§ãããäžæã
ãå°¿çŽ è¡æŒ¿æ¿åºŠãæµäœä¿æãŸãã¯ãã¢ãžãæäžã«
察å¿ããé«è¡å§çãšå ±ã«ååšããå Žåããã®æå¢
å ããå°¿çŽ æåºãèªå°ããããšã¯âãã®è¡æ¶²ã¬ã
ã«ãäœäžãããããšã¯åççã§ããããã«æãã
ãã å¿èè¡ç®¡è çŸæ£ã®å¢å ããå°¿çŽ è¡æ¶²ã¬ãã«ã¯è©
䟡ããããããããã«æ®éã§ãããå¢å ããå°¿çŽ
ã®æµãã¯å°¿çŽ æåºãå¢å ããããå©å°¿å€ããã³ã¢
ãã¬ããªã³é®æå€ã¯å°¿çŽ è¡æ¶²ã¬ãã«ãããã«å¢å
ãããããã§ãããå¡©ããã³å°¿çŽ ä¿æã®ãã®ææ¡
ããçžäºã®é¢ä¿æ§ãèæ ®ããŠé«è¡å§çã®å¡©åææ³
å©å°¿æ²»çã¯åççãªæ²»çæ¹æ³âå¡©åææ³âå€å°¿æ¯
䜵çšæ²»çã®ååã ããæå³ãããããæ æ¬çºæã«
ããã°æ¬æ现æžäžã«èšèŒãããã©ãžã³é žèªå°äœã®
䜿çšãé»è§£è³ªããã³æ°Žå¹³è¡¡å³ã¡ãåç平衡ã®ããª
ãçŽæ¥çãªå¶åŸ¡ãå¯èœã«ããããããŠçµç¹æµäœäžŠ
ã³ã«çŽ°èå€æµäœã®çŽæ¥èª¿æŽãäŸããããšã«ãã€ãŠ
æ¬çºæã®æ²»çã®å¹çšãæ¡å€§ãããæ¬çºæã¯æµžé床
調ç¯ã«ãã€ãŠé»è§£è³ªããã³æ°Žå¹³è¡¡ã®åŠçã«æ³šç®ã
ãæ°èŠãªãããŠçºå±ãããæ¹æ³ãæäŸããã åŸã€ãŠæ¬çºæã¯é«è¡å§çã®æ²»çãé žâå¡©åºå¹³è¡¡
ã劚害ãããå±éºããªãæµäœã®çµç¹æ»æºã®è»œæžã«
察ããè¡åŸåŠçãææã®éæãå¿ èŠãšãããŸãã¯
å¿ èŠãšããªãæ¥æ§ãŸãã¯æ ¢æ§å€å°¿æ¯çã®åŠçãã
ã³èºåèæµ®è «ã®æ²»çã®æç¶æ²»çã«å¯ŸããŠæäŸã
ãã 次ã«å®æœäŸã¯å¡©åææ³å€ããã€ããã¯ãããã¢
ãžãã®ååšãŸãã¯äžåšã§ãããŠã¢ããã©ã€ãã®ã
ã«ãªãé¡äŒŒäœã«ãã€ãŠäŸç€ºãããä»ã®ãã©ãžã³é ž
ååç©ãšå¯Ÿæ¯ããŠæ¬çºæã§å©çšãããã©ãžã³é žèª
å°äœã®å€å°¿äœçšãå ·äœçã«ç€ºãããã«åœ¹ç«ã€ãã®
ã§ããã å®æœäŸ ïŒ é£ç©ããã³æ°Žãéã®ãã«ããã¢ã³ã³ãŒãããŠã³
ãã«äžæ©äžããã«ããããïŒåã®ç¶æéè€20åã³
ã³ãããŒã«ã¯ãªã¢ã©ã³ã¹æéã®æåãå§ãŸã20å
åã«ã¯ã¬ã¢ããã³ïŒïœãç®äžã«äžããããã®åŸçŽ
ã¡ã«æ³šå ¥é床3.0mgïŒKgïŒïœãç¶æããã®ã«åå
ãªè©Šéšååç©ãå«æãã260mOsmïŒïŒ¬ãã³ãã
ãŒã«âPO4ç·©è¡æ¶²ã®1.0mlïŒåéèå 泚å°ãïŒé
èå ã«æ³šå ¥ãã2.0mgïŒKgåç¬æçšéãå ããŠïŒ
å§ããå®éšäžç¶ããã10ååŸããã«ã¯ã¬ã¢ããã³
1.0ïœãç®äžæ³šå°ãããã¯ã¬ã¢ããã³ã¯ãªã¢ã©ã³
ã¹ã糞çäœéé床ã®æž¬å®ã«äœ¿çšããã éèå 泚å°ãå§ããŠ20ååŸãé£ç¶ïŒåã®20åã¯
ãªã¢ã©ã³ã¹ã®æåã次ã®ïŒæéã«ããã€ãŠå®æœã
ããè¡æŒ¿ããã³å°¿æšæ¬ãå°¿çŽ ãæã å°¿é žããããª
ãŠã ãã¯ãã©ã€ããã«ãªãŠã ãã¯ã¬ã¢ããã³ãã
ã³å°¿çŽ ãå å«ããPHããã³æµåé床ã«å¯ŸããŠåæ
ããã ãã©ãžãã€ã«ã°ã¢ããžã³ã¯å°¿çŽ ã®æŽ»æ§ååžåã
é»å®³ãããã«ããã¢ã³ã®å°¿çŽ è¡æŒ¿æ¿åºŠãäœäžãã
ããè¡šãå°¿çŽ è¡æŒ¿æ¿åºŠãäœäžãããå°¿çŽ ããã
ãªãŠã ããã³ã«ãªãŠã ã®æåºãå¢å ãããããã¯
ãã©ã€ãã®æåºã®å¹æã¯å¯å€çã§ãã€ããå°¿é žæ
åºã¯åœ±é¿ãåããªãã€ãã ïŒâã¢ãããã©ãžãã€ã«ã°ã¢ããžã³ããã©ãžã
ã€ã«ã°ã¢ããžã³ã«å¯Ÿããã®ãšåããããã³ãŒã«ã«
åŸã€ãŠãã«ããã¢ã³ã«æäžããå Žåãå°¿çŽ ã¯ãªã¢
ã©ã³ã¹æ¯çããã³è¡æ¶²ã¬ãã«ã®çµæïŒè¡šïŒã¯ã
ã©ãžãã€ã«ã°ã¢ããžã³ïŒè¡šïŒã«å¯Ÿãããããã
ãã«äœããã®ã§ãã€ããäºã€ã®ååç©ã®ãããªãŠ
ã å©å°¿å¹æã¯åæ§ã§ãã€ããããã©ãžãã€ã«ã°ã¢
ããžã³ã¯ã«ãªãŠã å©å°¿å¹æã®æ¹ã倧ããã€ããã¯
ãã©ã€ãã§ã¯æ°å¹ã®ã€ãã«ããã«å€åããããé
ã«å°¿ã®PHã«é¢é£ããã è¡šã«ç€ºãããããã«ã¢ããã©ã€ãã®ãã«ãšã
é¡äŒŒäœã¯ãã«ããã¢ã³ã®å°¿çŽ ã®å°¿çŽ°ç®¡åæ³ãéåžž
ã«äœäžããããå¹æã¯çŽã¡ã«ã§ãããå°¿äžã®å°¿çŽ
æ¿åºŠã確å®ã§ããªãã»ã©äœãç¹ã«é²è¡ãããå°¿çŽ
è¡æŒ¿æ¿åºŠã¯ãã®æåºãäœäžããã«ã€ããŠå®è³ªçã«
å¢å ããã管è ãžã®æŽ»æ§å°¿çŽ åæ³ã®é»å®³ã¯ããã
ã®çµæã®èµ·ããããªè§£éã«æãããããã«ããã¢
ã³ã®ã¢ããã©ã€ãã®ãã«ãªãé¡äŒŒäœã®å®éšã¯å°¿çŽ
æµãçŽ2.0mlïŒåãç¶æããããã«ïŒmlïŒåã«ã
ããŠååãªãã³ãããŒã«éèå 泚å°ïŒ10ïŒ ïŒæº¶æ¶²
ã®ååšäžã§ç¹°ãè¿ããããã®å°¿ã®æµãã¯å°¿çŽ éæ¡
æ£ãæå°ã«ããã®ã«ååã§ãã€ãã éæ¡æ£ãæå°ã«ããããã«çŽ2.0mlïŒåã«å°¿ã®
æµããç¶æããå Žåã¢ããã©ã€ãã®ãã«ãªãé¡äŒŒ
äœã¯ã³ã³ãããŒã«å€ã®åå以äžã«å°¿çŽ ã¯ãªã¢ã©ã³
ã¹ãäœäžããè¡šãããŠå°¿çŽ è¡æŒ¿æ¿åºŠãå¢å€§ã
ãã糞çäœéé床ã¯äžå®ã®ãŸãŸã§ããããå°¿é ž
ã¯ãªã¢ã©ã³ã¹ã¯ã³ã³ãããŒã«å€ã®åå以äžã«åå
ç©ã«ãã€ãŠäœäžãããã®è¡æŒ¿æ¿åºŠã¯ãããã«å¢å€§
ããããããªãŠã ããã³ã¯ãã©ã€ãæåºã¯ã«ãªãŠ
ã ããå¢å ããã äžèšã«èšèŒããããŒã¿ã¯ä»¥äžã®è¡šâã«ç€ºã
ããã
æçšãªç¹å®ã®ãã©ãžã³é žèªå°äœããã³äœ¿çšããã
掻æ§æåã該ãã©ãžã³é žèªå°äœã®äžçš®ã§ããçµæ
ç©ããã³é«è¡å§çãçæ£çºäœãå°¿æ¯çããã³é¡äŒŒ
ã®çŸç ã®æ²»çæ¹æ³ã§ããã æ¬çºæã¯ãŸãå€å°¿å€ãšããŠæçšãªç¹å®ã®ãã©ãž
ã³é žèªå°äœãšçš®ã ã®å¡©åææ³å€ã®æ··åç©ããã³äœ¿
çšããã掻æ§æåã該ãã©ãžã³é žèªå°äœã®äžçš®ãš
å¡©åææ³å€ã®æ··åç©ã§ããå»è¬çµæç©ããã³é«è¡
å§çã®æ²»çæ¹æ³ã«é¢ãããã®ã§ããã ãããå å«ããåºä¹³åç©ã«ãããŠå°¿çŽ ã¯çªçŽ 代
è¬ã®äž»ãªæçµç£ç©ã§ãããå°¿çŽ ã¯ããã«æ¯æ§ã®ã¢
ã³ã¢ãã¢ããã³äºé žåççŽ ãããªã«ããã³âå°¿çŽ
ãµã€ã¯ã«ã®äžéç©ã«ããäœå ã§åæããããçŽ25
ïœã®å°¿çŽ ãïŒæ¥åœãããã®äœå ã§åæããããŸã
è èãéã€ãŠææ³ãããã å°¿çŽ ããã³ãããªãŠã ïŒå¡©åç©ïŒã¯äœã®äž»èŠãª
浞é掻æ§æåãæ§æããããã®æµžéã®åœ¹å²ã¯äºã€
ã®å°¿çŽ ããã³å¡©ã«å¯ŸããŠé¡äŒŒããŠããããéèŠãª
ç¹ã§ç°ãªã€ãŠãããå¡©åãããªãŠã ã¯ããå€å æº
ããåŸãªããã°ãªããããããªãŠã ã®ååžã¯å®è³ª
çã«è¡æŒ¿æ°Žãå å«ãã现èå€æµäœã«éå®ãããã
å°¿çŽ ã¯å€§éã«äœå ã§åæããããã®ååžã¯çŽ°èå
ããã³çŽ°èå€ã®äž¡æ¹ã§ããäžç·äœæ°Žã«ç䟡ã§ã
ããïŒã«ãªãŠã ã¯çŽ°èå€ã§ãããªãŠã ã«ãã€ãŠãš
ããã现èå 浞éã®åœ¹å²ãã¯ãããïŒ éå°ãªãããªãŠã ãäžååãªè äœçšã«ãã€ãŠæ¶
è²»ãããŸãã¯ç¶æãããå Žåãå浞éå§ã¯æžãã®
åºæ¿å¢å æµäœæ¶è²»ããã³è¡å§ã®å¢å€§ããã³ïŒãŸã
ã¯ä¹³è «ã«å°ããŠããŸãæµäœä¿æã«ãã€ãŠç¶æãã
ãã å°¿çŽ ææ³ãäœäžãããã®ã«ååãªæå·è äœçšã®
ååšäžãã®èç©ã¯ããå浞éå§é¢ä¿æ§ãæµäœèç©
ã«ãã€ãŠç¶æãããå Žåã现èå 䞊ã³ã«çŽ°èå€æµ
äœèç©ãå¢å€§ãããã®ã«ååã§ããããšãã§ã
ããå³ããç¶æ³äžã§ã¯å°¿æ¯çãçããŠããŸããå°¿
æ¯çã®çç¶äžŠã³ã«åŸŽåã«å¯ŸããŠæã説æãããã®
ã¯ãã®çŽ°èå ïŒçŽ°èå€èç©ã§ãããå°¿çŽ ããã³äœ
æ°Žã¬ãã«ã®è»œçå°¿æ¯çã®äžæã«ãããŠçç¶ã¯å¡©ä¿
æãšå®å šã«æ··åããããšãã§ãããã®å Žåå¡©åæ
æ³ãŸãã¯å€å°¿çã«åºã¥ãæ²»çã¯ããçšåºŠãŸã§ã¯äº€
æããŠçšããããšãã§ããã èšåºç¥èã®çŸåšã®äºæ ã¯å°¿çŽ ãè èã®ç³žçäœã«
ãããŠè¡æŒ¿æ°Žã§éããéããå°¿çŽ ããããã³
ã«ããå°¿çæã®éçšã«ãããŠååéæ¡æ£ãåãã
ããšãèªããŠãããå°¿çŽ ã®ååéæ¡æ£ã¯éæ¬é床
ã®å¢å€§å³ã¡ãå°¿æµåã®å¢å ã«ãã€ãŠäœäžãåŸãã å¢å€§ããéæ¬é床ã¯(1)æ²»ç芳ç¹ããèªãç¡å¹ã§
ããäœæ¶²å®¹éãå¢éãããããšã«ãã€ãŠã(2)倧é
ãéçµå£çã«æäžããããšã®å¿ èŠã®ããã«å®çšç
ã§ãªã浞éå©å°¿å€ãäŸãã°ãã³ãããŒã«ã®å©ãã§
ãŸãã¯(3)äžæãé»è§£è³ªå¹³è¡¡ãå€ããã®ã«ååãªçš
éã§æå¹ãªå¡©åææ³å€ãçšããããšã«ãã€ãŠèªçº
ããããšãã§ããã æ¬çºæã«ããã°åºä¹³åç©ã®è èãå°¿çŽ ã掻çºã«
åæ³ããã³ååžåãããã«ç³žçäœã§éããããŠ
ååéæ¡æ£ãåããããšãã§ããããšãçºèŠã
ãã ããã«ãã®äžãæ¬çºæã§å©çšããããã©ãžã³é ž
èªå°äœã¯åªäœã«å°¿çŽ ã®æŽ»æ§è è尿现管ååžåãé»
害ããããšãã§ãããã¢ããã©ã€ãã®ãã«ãªãé¡
䌌äœã®ãããªä»ã®ãã©ãžã³é žèªå°äœã¯å°¿çŽ ã®æŽ»æ§
ååžåãéèŠã«ãé»å®³ããã«å°¿çŽ ã®æŽ»æ§å°¿çŽ°ç®¡å
æ³ãåªäœã«é»å®³ããããšãçºèŠãããããããäž
ã§çŽ°èããã³çŽ°èèã®æµžéæ§èª¿ç¯äœçšã«åœ±é¿ãå
ãŒãããšãã§ãã城åãšããŠå°¿çŽ è¡æ¶²ã¬ãã«ãäœ
äžããå°¿ã®æµžéæ¿åºŠãå¢å€§ãããåŸã€ãŠãããã¯
æ²»çäžãããã®åœ¹å²ãåäžèŠããããã«æµžé調ç¯
å€ãšåŒã¶ããšãã§ããããããã®æå¹æ§ã¯è»œåºŠã®
é«è¡å§çã®åŠçããçæ£çºäœããã³ïŒãŸãã¯å°¿æ¯
çã®æªæ§ãŸãã¯é床ã®é«è¡å§çã®ç¥çµåŠççåãŸ
ã§åãŒããšã¿ãªããããçš®ã ã®å¡©åææ³å€ãšäœµçš
ãããããã®æå¹æ§ã¯è»œåºŠã®é«è¡å§çããã³èºå
èæµ®è «ã®åŠçããæªæ§ãŸãã¯é床ã®é«è¡å§çã®ç¥
çµåŠççåãŸã§åãŒããšã¿ãªãããã ã¯ã©ãŽãšç±³åœç¹èš±ç¬¬3313813å·ã¯ã«ãªãŠã ã€ãª
ã³ã®æåºãå¢å ãããã«ãããªãŠã ã€ãªã³ã®æåº
ãéžæçã«å¢å ããå©å°¿å€ããããªãŠã ææ³å€ãš
ããŠã®ïŒâã¢ããâïŒïŒïŒâãžçœ®æâãã©ãžãã€
ã«ã°ã¢ããžã³ããã³ãããã®çšéãèšèŒããŠã
ãã V.Gen.Ppysiol.第68(1)å·»ã第43ã63é ïŒ1976
幎ïŒã®ããã¹çã¯åé¢ããã«ãšã«ã®ç®èããã³è
質èèã«ãããã«ããªã³éæ¬ã«ã¢ããã©ã€ããã
ã³ãã®é¡äŒŒäœã®ããã€ãã®å¹æãèšèŒããŠããã ããããªãããããã®æç®ã¯ãã©ãžã³é žèªå°äœ
ã®å€å°¿å€æŽ»æ§ã瀺åããŠãããã該èªå°äœã該åŒ
äŸã«èšèŒããèŠä»¶ã«åŸã€ãŠæçšã§ããååãªå¡©å
ææ³ããã³æã«ãªãŠã ææ³äœçšãæããªãããšã
ãããããã®æ¹æ³ã®äžèšåŒäŸãé«è¡å§çãçæ£çº
äœãå°¿æ¯çãªã©ã®æ²»çã«å¯ŸããŠæ¬çºæã§å©çšãã
ãç¹å®ã®ãã©ãžã³é žèªå°äœå€å°¿å€ã®äœ¿çšã瀺åã
ãŠããªãã æ¬çºæã«ããã°å»è¬çã«äœ¿çšãåŸãæ äœããã³
æ²»çäžæå¹éã®åŒïŒ ãåŒäž ã¯ïŒ¯ãŸãã¯NHã§ããã ã¯OHãNHCONR4R5ãŸãã¯ïŒ®ïŒïŒ£ïŒNR4
R5ïŒ2 ã§ãããïŒåŒäžR4ããã³R5ã¯åã æ°ŽçŽ ãçŽéãŸã
ã¯åæéC1-10ã¢ã«ãã«ãã¢ãªãŒã«C1-4ã¢ã«ãã«ã
眮æåºããã«ãªããã¯ãããããã¢ããšãŒããŸã
ã¯çŽéãŸãã¯åæéã§ããã¢ããŸãã¯çœ®æã¢ãªãŒ
ã«C1-4ã¢ã«ãã«ãããªã矀ããéžæããããïŒ R1ããã³R2ã¯åã æ°ŽçŽ ãã¢ããããã³çœ®æåº
ãçŽéãŸãã¯åæéC1-10ã¢ã«ãã«ãŸãã¯C3-8ã·
ã¯ãã¢ã«ãã«ã§ããã¢ããŸãã¯ãžçœ®æã¢ãããã
ãªã矀ããéžæããããäœãR1ããã³R2ã¯äž¡æ¹
ãã¢ãããŸãã¯çœ®æã¢ããã§ããããšãã§ããªã
ããã³ R3ã¯æ°ŽçŽ ããã«ãªããã¯ãããããã¢ãŸãã¯
ãšãŒãã§ãããã ãæããååç©ããã³ãã®å»è¬çã«äœ¿çšãåŸãå¡©
ãããªãå€å°¿å€çšéã®å»è¬çµæç©ãæäŸããã æ¬çºæã«ããã°ããã«å»è¬çã«äœ¿çšãåŸãæ äœ
ããã³æ²»çäžæå¹éã® (a) åŒã®ååç©ããã³ (b) ãšã¿ã¯ãªããã¯ã¢ã·ãããããã»ããããã¡
ã¿ãããã ãŸãªãã³ãã¯ãããã¢ãžãããã³ã
ã€ããã¯ãããã¢ãžããå å«ãããã³ãŸãã¢ãž
ã¢ãžã³ãã¯ããã¿ãªãã³ãããã¿ãŸã³ãã¡ãã
ãŸã³ãã€ã³ãã¯ãªãã³ãã¢ã»ã¿ãŸãŒã«ã¢ããã
ãšããã·ãŸãŒã«ã¢ããããã³ã¡ã¿ãŸãŒã«ã¢ãã
ãããªã矀ããéžæãããå¡©åææ³å€ ã®æ··åç©ãããªãé«è¡å§çããã³æµ®è «ã®æ²»çã«å¯Ÿ
ããå»è¬çµæç©ãæäŸããã æ¬çºæã®å¥œé©ãªååç©ã¯ïŒ¹ããŸãã¯NHã§ã
ããR1ããã³R2ã®äžã€ãæ°ŽçŽ ãŸãã¯ã¢ããã§ã
ããä»ãæ°ŽçŽ ã§ããããã³R3ãæ°ŽçŽ ã§ããåŒ
ã®ååç©ã§ãããæ¬çºæã®å¥œé©ãªæ··åç©ã¯åŒã®
奜é©ãªååç©ã䜿çšããå¡©åææ³å€ããã€ããã¯
ãããã¢ãžãã§ããååç©ã§ããã æ¬çºæã®ç¹ã«å¥œé©ãªååç©ã¯æ¬¡ã®ãã®ã§ããã ãã©ãžãã€ã«ã°ã¢ããžã³ã ïŒâã¢ãããã©ãžãã€ã«ã°ã¢ããžã³ åŒååç©ã¯ç¡æ©ãŸãã¯ææ©é žããèªå°ããã
å¡©ã®åœ¢æ ã§çšããããšãã§ããã次ã®ãã®ããã
ãå¡©ã«å å«ãããïŒé ¢é žå¡©ãã¢ãžãã³é žå¡©ãã¢ã«
ã®ãã³é žå¡©ãã¢ã¹ãã©ã®ã³é žå¡©ãå®æ¯éŠé žå¡©ãã
ã³ãŒã³ã¹ã«ãã³é žå¡©ãéç¡«é žå¡©ãé ªé žå¡©ãã¯ãšã³
é žå¡©ãã·ãšãŠããŠé žå¡©ãã«ã³ãã«ã¹ã«ãããŒãã
ã·ã¯ããã³ã¿ã³ããããªããŒãããžã°ã«ã³ããŒ
ããããã·ã«ãµã«ããšãŒãããšã¿ã³ã¹ã«ãããŒ
ããããã«é žå¡©ãã°ã«ã³ããã¿ããšãŒãããããµ
ã³é žå¡©ãå¡©é žå¡©ãèåæ°ŽçŽ é žå¡©ããšãŠåæ°ŽçŽ é ž
å¡©ãïŒâããããã·ãšã¿ã³ã¹ã«ãããŒããä¹³é ž
å¡©ããã¬ã€ã³é žå¡©ãã¡ã¿ã³ã¹ã«ãã³é žå¡©ãïŒâã
ãã¿ã¬ã³ã¹ã«ãã³é žå¡©ããã³ãã³é žå¡©ãã·ãŠãŠé ž
å¡©ããã¢ãšãŒãããã¯ãã³é žå¡©ãéç¡«é žå¡©ãïŒâ
ããšãã«ããããªã³é žå¡©ããã¯ãªã³é žå¡©ãããã«
é žå¡©ãããããªã³é žå¡©ãã³ãã¯é žå¡©ãé ç³é žå¡©ã
ããªã·ã¢ã³é žå¡©ããã·ã¬ãŒãããã³ãŠã³ãã«ã³é ž
å¡©ããŸãå¡©åºæ§çªçŽ âå«æåºãå¡©åãèåããã³
ãšãŠåã¡ãã«ããšãã«ããããã«ããã³ããã«ã®
ãããªäœçŽã¢ã«ãã«ãã©ã€ãããžã¡ãã«ããžãšã
ã«ããžããã«ã®ãããªãžã¢ã«ãã«ã¹ã«ããšãŒãã
ãã³ãžã¢ãã«ã¹ã«ããšãŒããå¡©åãèåããã³ãš
ãŠåããã·ã«ãã©ãŠãªã«ãããªã¹ãã«ããã³ã¹ã
ã¢ãªã«ã®ãããªé·éãã©ã€ãããã³ãžã«ããã³ã
ãšããã«ãããã€ãã®ãããªã¢ã©ã«ãã«ãã©ã€ã
ãªã©ã®è¬å€ã§ç¬¬åçŽåããããšãã§ãããæ°ŽãŸã
ã¯æ²¹æº¶æ§ãŸãã¯åæ£æ§çæç©ãããã«ãã€ãŠåŸã
ããã æ¬çºæã®ãã©ãžã³é žèªå°äœã¯é«åºŠã®å€å°¿äœçšã
æããããããã¯é«è¡å§çã®æ²»çã«æçšã§ããã
äžè¬ã«ãããã¯äžæããå°¿çŽ ã¬ãã«ãæãããªã
ãªãæ§ã ãªçç¶ã«å¯ŸããŠç€ºãããããã®ã«ããŽãª
ãŒã®äžã«çæ£çºäœããã³å°¿æ¯çã®ãããªçŸç ãå
å«ãããã æ¬çºæã®ãã©ãžã³é žèªå°äœããã³å¡©åææ³å€æ··
åç©ã¯é«åºŠã®å€å°¿ããã³å¡©åææ³ïŒå©å°¿äœçšãæ
ãããåŸã€ãŠãããã¯é«è¡å§çããã³æµ®è «ã®æ²»ç
ã«æçšã§ããã ãããã®ç®çã«å¯ŸããŠæ¬çºæã®ååç©ããã³æ··
åç©ã¯éäŸç¡æ¯æ§ã®å»è¬çã«äœ¿çšãåŸãæ äœãè£
å©è¬ããã³è³Šåœ¢å€ãå«æããçšéåäœåŠæ¹ã§çµå£
çã«ãå±æçã«ãéçµå£çã«ãåžå ¥ã¹ãã¬ãŒã«ã
ã€ãŠãŸãã¯çŽè žçã«æäžããããšãã§ãããæ¬æ
现æžã§çšããããéçµå£ãªãçšèªã¯ç®äžæ³šå°ãé
èå ãçèå ãèžéªšå 泚å°ãŸãã¯æ³šå ¥æè¡ãå å«
ãããããŠã¹ãã©ããããŠããã€ãããã³ãªã©ã®
ãããªæž©è¡åç©ã®æ²»çã®ä»ã«ãæ¬çºæã®ååç©ã¯
ããã®æ²»çã«æå¹ã§ããã 掻æ§æåãå«æããå»è¬çµæç©ã¯äŸãã°é å€ã
ãããŒãå€ãããŒã³ãžå€ãæ°Žæ§ãŸãã¯æ²¹æ§æžæ¿æ¶²
å€ãåæ£æ§æ£å€ãŸãã¯é¡ç²å€ãä¹³å€ç¡¬ãŸãã¯è»ã«
ãã»ã«å€ãã·ãããå€ãŸãã¯ãšãªãã·ã«å€ã®çµå£
çšã«é©åœãªåœ¢æ ã«ããããšãã§ãããçµå£çšã«äŒ
å³ãããçµæç©ã¯å»è¬çµæç©ã®è£œé ã«å¯ŸããŠåœè©²
æè¡ã«å ¬ç¥ã®ããããæ¹æ³ã«åŸã€ãŠèª¿è£œããããš
ãã§ãããããçµæç©ã¯å»è¬çã«ãšã¬ã¬ã³ããªã
ããŠçŸå³ãªè£œå€ãæäŸããããã«çå³å€ãéŠå³
å€ãçè²å€ããã³é²è å€ãããªã矀ããéžæãã
ãïŒçš®ãŸãã¯ãã以äžã®è¬å€ãå«æããããšãã§
ãããé å€ã¯é å€ã®è£œé ã«é©åœãªç¡æ¯æ§ã®å»è¬ç
ã«äœ¿çšãåŸã賊圢å€ãšæ··åãã掻æ§æåãå«æã
ãããããã®è³Šåœ¢å€ã¯äŸãã°çé žã«ã«ã·ãŠã ãç
é žãããªãŠã ãä¹³ç³ããªã³é žã«ã«ã·ãŠã ãŸãã¯ãª
ã³é žãããªãŠã ã®ãããªäžæŽ»æ§åžéå€ãé¡ç²åã
ãã³åŽ©å£å€ãäŸãã°ã³ãŒã³ã¹ã¿ãŒããŸãã¯ã¢ã«ã®
ã³é žãçµåå€ãäŸãã°ã¹ã¿ãŒãããŒã©ãã³ãŸãã¯
ã¢ã©ãã¢ãŽã ããã³æœ€æ»å€ãäŸãã°ã¹ãã¢ãªã³é ž
ãã°ãã·ãŠã ãã¹ãã¢ãªã³é žãŸãã¯ã¿ã«ã¯ã§ãã
ããšãã§ãããé å€ã¯æªè¢«èŠã§ããããšãã§ãã
ããã¯èè žç®¡ã®åŽ©å£ããã³åžåãé ãããããã«
ãã€ãŠé·æéã«ããã€ãŠç¶æãããäœçšãæäŸã
ãããã«å ¬ç¥ã®æè¡ã«ãã€ãŠè¢«èŠããããšãã§ã
ããäŸãã°ã°ãªã»ãªã«ã¢ãã¹ãã¢ã¬ãŒããŸãã¯ã°
ãªã»ãªã«ãžã¹ãã¢ã¬ãŒãã®ãããªæéé 延ç©è³ªã
åç¬ã§ãŸãã¯ã¯ãã¯ã¹ãšãšãã«äœ¿çšããããšãã§
ããã çµå£çšã®åŠæ¹ããŸã掻æ§æåãäžæŽ»æ§åºäœåžé
å€ãäŸãã°çé žã«ã«ã·ãŠã ããªã³é žã«ã«ã·ãŠã ãŸ
ãã¯ã«ãªãªã³ãšæ··åãã硬ãŒã©ãã³ã«ãã»ã«å€ãš
ããŠãŸãã¯æŽ»æ§æåãæ°ŽãŸãã¯æ²¹åªè³ªãäŸãã°èœ
è±çæ²¹ãããŒããæ²¹ãæµåãã©ãã€ã³ãŸãã¯ãªãª
ãŒãæ²¹ãšæ··åããè»ãŒã©ãã³ã«ãã»ã«å€ãšããŠäž
ããããšãã§ããã æ°Žæ§æžæ¿æ¶²å€ã¯æ°Žæ§æžæ¿æ¶²ã®è£œé ã«é©åœãªè³Šåœ¢
å€ãšæ··åãã掻æ§ç©è³ªãå«æãããããã賊圢å€
ã¯æ²æ®¿é²æ¢å€ãäŸãã°ãããªãŠã ã«ã«ããã·ã¡ã
ã«ã»ã«ããŒã¹ãã¡ãã«ã»ã«ããŒã¹ãããããã·ã
ããã«ã¡ãã«ã»ã«ããŒã¹ãã¢ã«ã®ã³é žãããªãŠ
ã ãããªããã«ãããªãã³ããã©ã¬ã³ããŽã ãã
ã³ã¢ã©ãã¢ãŽã ã§ãããåæ£å€ãŸãã¯æ¹¿æœ€å€ã¯å€©
ç¶ã®ãã¹ãã¢ãããäŸãã°ã¬ã·ãã³ãŸãã¯ã¢ã«ã
ã¬ã³ãªããµã€ããšèèªé žãšã®çž®åçæç©ãäŸãã°
ããªãªãã·ãšãã¬ã³ã¹ãã¢ã¬ãŒããŸãã¯ãšãã¬ã³
ãªããµã€ããšé·éèèªæã¢ã«ã³ãŒã«ãšã®çž®åçæ
ç©ãäŸãã°ããã¿ãã«ãšãã¬ã³ãªãã·ã»ã¿ããŒã«
ãŸãã¯ããªãªãã·ãšãã¬ã³ãœã«ãããŒã«ã¢ããªã¬
ãšãŒãã®ãããªèèªé žãšããã·ããŒã«ããèªå°ã
ããéšåãšã¹ãã«ãšãšãã¬ã³ãªããµã€ããšã®çž®å
çæç©ãŸãã¯ãšãã¬ã³ãªããµã€ããšèèªé žããã³
ããã·ããŒã«ç¡æ°Žç©ããèªå°ãããéšåãšã¹ãã«
ãšã®çž®åçæç©ãäŸãã°ããªãªãã·ãšãã¬ã³ãœã«
ãã¿ã³ã¢ããªã¬ãšãŒãã§ããã該氎æ§æžæ¿æ¶²ããŸ
ãïŒçš®ãŸãã¯ãã以äžã®é²è å€ãäŸãã°ãšãã«ãŸ
ãã¯ïœâãããã«ïœâããããã·ãã³ãŸãšãŒãã
ïŒçš®ãŸãã¯ãã以äžã®çè²å€ãïŒçš®ãŸãã¯ãã以
äžã®éŠå³å€ããã³ã¹ã¯ããŒã¹ãŸãã¯ãµãã«ãªã³ã®
ãããªïŒçš®ãŸãã¯ãã以äžã®çå³å€ãå«æããã
ãšãã§ããã æ²¹æ§æžæ¿æ¶²å€ã¯æŽ»æ§æåãæ€ç©æ²¹ãäŸãã°èœè±
çæ²¹ããªãªãŒãæ²¹ããŽãæ²¹ãŸãã¯ã€ã·æ²¹äžã«ãŸã
ã¯æµåãã©ãã€ã³ã®ãããªé±ç©æ²¹äžã«æžæ¿ããã
ããšã«ãã€ãŠåŠæ¹ããããšãã§ãããæ²¹æ§æžæ¿æ¶²
å€ã¯æ¿ååå€äŸãã°ããããŠãåºåœ¢ãã©ãã€ã³ãŸ
ãã¯ã»ãã«ã¢ã«ã³ãŒã«ãå«æããããšãã§ããã
äžèšã§ç€ºãããããªçå³å€ããã³éŠå³å€ãçŸå³ãª
çµå£è£œå€ãæäŸããããã«æ·»å ããããšãã§ã
ãããããã®çµæç©ã¯ã¢ã¹ã³ã«ãã³é žã®ãããªæ
é žåå€ã®æ·»å ã«ãã€ãŠä¿åããããšãã§ããã æ°Žã®æ·»å ã«ãã€ãŠæ°Žæ§æžæ¿æ¶²ã®èª¿è£œã«é©åœãªå
æ£å€ããã³é¡ç²å€ã¯åæ£å€ãŸãã¯æ¹¿æœ€å€ãæ²æ®¿é²
æ¢å€ããã³ïŒçš®ãŸãã¯ãã以äžã®é²è å€ãšæ··åã
ã掻æ§æåãæäŸãããé©åœãªåæ£ãŸãã¯æ¹¿æœ€å€
ããã³æ²æ®¿é²æ¢å€ã¯äžèšã§æ¢ã«èšåãããã®ã«ã
ã€ãŠäŸç€ºããããããã«è³Šåœ¢å€ãäŸãã°çå³å€ã
éŠå³å€ããã³çè²å€ããŸãååšãããããšãã§ã
ãã æ¬çºæã®å»è¬çµæç©ã¯ãŸãæ°Žäžæ²¹åãšãã«ãžãš
ã³ã®åœ¢æ ã«ããããšãã§ãããæ²¹çžã¯æ€ç©æ²¹ãäŸ
ãã°ãªãªãŒãæ²¹ãŸãã¯èœè±çæ²¹ãŸãã¯é±ç©æ²¹ãäŸ
ãã°æµåãã©ãã€ã³ãŸãã¯ãããã®æ··åç©ã§ãã
ããšãã§ãããé©åœãªä¹³åå€ã¯å€©ç¶ãŽã ãäŸãã°
ã¢ã©ãã¢ãŽã ãŸãã¯ãã©ã¬ã³ããŽã ã倩ç¶ãã¹ã
ã¢ãããäŸãã°å€§è±æ²¹ã¬ã·ãã³ããã³èèªé žãã
ã³ããã·ããŒã«ç¡æ°Žç©ããèªå°ããããšã¹ãã«ãŸ
ãã¯éšåãšã¹ãã«ãäŸãã°ãœã«ãã¿ã³ã¢ããªã¬ãš
ãŒãããã³è©²éšåãšã¹ãã«ãšãšãã¬ã³ãªããµã€ã
ã®çž®åçæç©ãäŸãã°ããªãªãã·ãšãã¬ã³ãœã«ã
ã¿ã³ã¢ããªã¬ãšãŒãã§ããããšãã§ãããä¹³å€ã
ãŸãçå³å€ããã³éŠå³å€ãå«æããããšãã§ã
ãã ã·ãããå€ããã³ãšãªãã·ã«å€ã¯çå³å€ãäŸã
ã°ã°ãªã»ããŒã«ããœã«ãããŒã«ãŸãã¯ã¹ã¯ããŒã¹
ã§åŠæ¹ããããšãã§ããããããåŠæ¹ã¯ãŸãä¿è·
å€ãé²è å€ããã³éŠå³å€ããã³çè²å€ãå«æãã
ããšãã§ãããå»è¬çµæç©ã¯æ» è泚å°çšè£œå€ã®åœ¢
æ ã«ãäŸãã°æ» è泚å°çšæ°Žæ§ãŸãã¯æ²¹æ§æžæ¿æ¶²ãš
ããŠããããšãã§ããããã®æžæ¿æ¶²ã¯äžèšã§èšå
ããé©åœãªåæ£ãŸãã¯æ¹¿æœ€å€ããã³æ²æ®¿é²æ¢å€ã
çšããŠå ¬ç¥ã®æè¡ã«åŸã€ãŠåŠæ¹ããããšãã§ã
ããæ» è泚å°çšè£œå€ããŸãç¡æ¯æ§ã®éçµå£çã«äœ¿
çšãåŸãåžéå€ãŸãã¯æº¶åªäžæ» è泚å°çšæ°Žæº¶æ¶²ãŸ
ãã¯æžæ¿æ¶²ãäŸãã°ïŒïŒïŒâãã¿ã³ãžãªãŒã«äžæº¶
液ãšããŠããããšãã§ããã䜿çšããããšãã§ã
ã䜿çšãåŸã賊圢å€ããã³æº¶åªã«ã¯æ°Žããªã³ã²ã«
液ããã³å¡©åãããªãŠã ç匵溶液ããããããã«
æ» èãäžæ®çºæ²¹ã溶åªãŸãã¯æžæ¿åªè³ªãšããŠéäŸ
䜿çšãããããã®ç®çã«å¯ŸããŠåæã¢ããŸãã¯ãž
ã°ãªã»ã©ã€ããå å«ããããããç¡åºæ¿äžæ®çºæ²¹
ã䜿çšããããšãã§ãããããã«ãªã¬ã€ã³é žã®ã
ããªèèªé žã¯æ³šå°çšå€ã®èª¿è£œã«äœ¿çšãèŠåºããã æ¬çºæã®ååç©ããã³æ··åç©ã¯ãŸãè¬å€ã®çŽè ž
æäžãšããŠåè¬ã®åœ¢æ ã§æäžããããšãã§ããã
ãããã®çµæç©ã¯è¬å€ãéåžžã®æž©åºŠã§åºäœã§ãã
ãçŽè žæž©åºŠã§æ¶²äœã§ããé©åœãªç¡åºæ¿è³Šåœ¢å€ãšæ··
åããããšã«ãã€ãŠèª¿è£œããããšãã§ããããæ
çŽè žå ã§è解ããŠè¬å€ãæŸåºããããããææã¯
ã³ã³ã¢ãã¿ãŒããã³ããªãšãã¬ã³ã°ãªã³ãŒã«ã§ã
ãã å±æçšãšããŠæŽ»æ§æåãå«æããã¯ãªãŒã å€ã
è»èããŒãªãŒå€ã液å€ãŸãã¯æžæ¿æ¶²å€ã䜿çšã
ãã åŒã®ååç©ã«å¯ŸããŠïŒæ¥åœãçŽ25ã750mgã®
çšéã¬ãã«ãäžèšã§ç€ºããçç¶ã®æ²»çã«æçšã§ã
ããå ·äœçã«ã¯é«è¡å§çã¯ïŒæ¥åœãäœéïŒKgã«ã€
ãååç©çŽ0.5ã15mgæäžããããšã«ãã€ãŠæå¹
ã«æ²»çããããæå©ã«ã¯äœéïŒKgåœãçŽïŒã15mg
ããã³ç¹ã«ïŒKgåœãçŽïŒã10mgæ¥çšéã極ããŠæ
å¹ãªçµæãçããã æ¬çºæã®æ··åç©ã®å¡©åææ³å€ãšããŠã®çšéã¬ã
ã«ã¯äžè¬ã«å¥ã ã®æ²»çãšããŠãããã®è¬å€ã«å¯Ÿã
ã確ç«ããçšéã«ããã äžåã®çšé圢æ ã補é ããããã«æ äœææãšæ··
åããããšãã§ãã掻æ§æåéã¯æ²»çããã宿䞻
ããã³ç¹å®ã®æäžæ¹æ³ã«äŸåããŠå€åãããäŸã
ã°ããã®çµå£æäžã«å¯ŸããŠäŒå³ãããåŠæ¹ã¯å šçµ
æç©ã®çŽïŒã95ïŒ ãå€åããããšãã§ããæ äœæ
æã®é©åœããã³éåžžéãšååãã掻æ§è¬å€25ã
750mgãå«æããããšãã§ãããçšéåäœåœ¢æ ã¯
äžè¬ã«æŽ»æ§æåçŽ25ã500mgãå«æããããšãã§
ããã ããããªããããããç¹å®æ£è ã«å¯ŸããŠç¹å®ã®
æçšéã¬ãã«ã¯äœ¿çšãããç¹å®ååç©ã®æŽ»æ§ã幎
什ãäœéãå šèº«ã®å¥åº·ãæ§ãé£é€ãæäžæéãæ
äžçµè·¯ãææ³é床ãè¬å€ã®äœµçšããã³æ²»çããç¹
å®çŸç ã®éããå å«ããæ§ã ãªå åã«äŸåããã æ¬çºæã«ããã°ããã«æ²»çäžæå¹ãªéã®åŒïŒ ïŒåŒäžïŒ¹ããR1ãR2ããã³R3ã¯äžèšãšåäž
ã®æå³ãæãããïŒ ãæããååç©ãæ²»çãå¿ èŠãšãã宿䞻ã«æäžã
ãããšãããªãé«è¡å§çã®æ²»çæ¹æ³ãæäŸãã
ãã ãªãããã«ãŸãæ¬çºæã«ããã°ãæ²»çäžæå¹ãª
éã®åŒïŒ ïŒåŒäžïŒ¹ããR1ãR2ããã³R3ã¯äžèšãšåäž
ã®æå³ãæãããïŒ ãæããååç©ãæ²»çãå¿ èŠãšããŠãã宿䞻ã«æ
äžããããšãããªãå€å°¿æ¯çç¶ã®æ²»çæ¹æ³ãæäŸ
ãããã ããã«æ¬çºæã«ããã° (a) åŒ ïŒåŒäžïŒ¹ããR1ãR2ããã³R3ã¯äžèšãšå
äžã®æå³ãæãããïŒ ãæããååç©ããã³ (b) å®è³ªçã«ãšã¿ã¯ãªããã¯ã¢ã·ãããããã»ã
ãããã¡ã¿ãããã ãŸãªãã³ãã¯ãããã¢ãžã
ããã³ãã€ããã¯ãããã¢ãžããå å«ãããã³
ãŸãã¢ãžã¢ãžã³ãããªã矀ããéžæãããå¡©å
ææ³å€ ã®æ··åç©ã®æ²»çäžæå¹ãªéãæ²»çãå¿ èŠãšããŠã
ã宿䞻ã«æäžããããšãããªãé«è¡å§çã®æ²»çæ¹
æ³ãæäŸãããã ãªãããã«ãŸãæ¬çºæã«ããã° (a) åŒ ïŒåŒäžïŒ¹ããR1ãR2ããã³R3ã¯äžèšãšå
äžã®æå³ãæãããïŒ ãæããååç©ããã³ (b) å®è³ªçã«ãšã¿ã¯ãªããã¯ã¢ã·ãããããã»ã
ãããã¡ã¿ãããã ãŸãªãã³ãã¯ãããã¢ãžã
ããã³ãã€ããã¯ãããã¢ãžããå å«ãããã³
ãŸãã¢ãžã¢ãžã³ãã¯ããã¿ãªãã³ãããã¿ãŸ
ã³ãã¡ãã©ãŸã³ãã€ã³ãã¯ãªãã³ãã¢ã»ã¿ãŸãŒ
ã«ã¢ããããšããã·ãŸãŒã«ã¢ããããã³ã¡ã¿ãŸ
ãŒã«ã¢ãããããªã矀ããéžæãããå¡©åææ³
å€ ã®æ··åç©ã®æ²»çäžæå¹ãªéãæ²»çãå¿ èŠãšããŠã
ã宿䞻ã«æäžããããšãããªãæµ®è «ã®æ²»çæ¹æ³ã
æäŸãããã åŒã®ååç©ã¯ãããªãŠã ãã¯ãã©ã€ãããã³
ã«ãªãŠã ã®å¢å€§ããæåºãå å«ããæçšéé¢é£æ¹
æ³ã§å°¿çŽ ãããååžåãé»å®³ããããããã®å¹æ
ã¯å°¿æµåºãšã¯ç¡é¢ä¿ã§ãããååéæ¡æ£ãæå°å
ããæ¡ä»¶äžã§å°¿çŽ ã¯ãªã¢ã©ã³ã¹ãã»ãŒç³žçäœé
çã«å¢å€§ãããã è è现管ã®ç®¡è ãžã®å°¿çŽ ã®åæ³ãé»å®³ãããã
ã®å€åãåŸãèœåããã©ãžã³é žèªå°äœã«ãããã
ãã¯æ¬çºæã®ãã©ãžãã€ã«ã°ã¢ããžã³ã§æå°ã§ã
ãããã«ããã¢ã³ã¹ã§ãã®å¹æã¯æçœã§ã¯ãªã
ããã¢ããã©ã€ãã®ãã«ãªãé¡äŒŒäœã¯éæ¡æ£ãæ
å°ã®æã§ãããå°¿çŽ åæ³ããã³æµäœæåºãã»ãšã
ã©å®å šã«é»å®³ãããã¹ãããâãããŒå®éšã«ãã
ãŠæŽ»æ§ååžåããã³åæ³ã®é»å®³ã説æããããšã
ã§ããã æ¬çºæã§å©çšãããåŒã®ååç©ã¯çµå£äžŠã³ã«
éçµå£æäžã§æŽ»æ§ã§ãããïŒâã¢ãããã©ãžãã€
ã«ã°ã¢ããžã³ãå³åº§ã«æãæå¹ã§ãããããã©ãž
ãã€ã«ã°ã¢ããžã³å¹æããã³è¡æ¶²ã¬ãã«ã¯æ倧å¹
æã«å¯ŸããŠæããè¿œå æéãå¿ èŠãšããã æ¢ã«ç€ºããéããæ¬çºæã§å©çšãããåŒã®å
åç©ã¯åœç¶æµžé調ç¯å€ãšåŒã¶ããšãã§ããã浞é
床調ç¯ã¯é 次æ°çš®ã®çžäºã«é¢ä¿ããå åãå å«ã
ãã ãããªãŠã ãã¯ãã©ã€ãããã³éçé žå¡©ã€ãªã³
ã®åèšãšããŠå¡©ã¯ããã®çŽ°èå€æ°Ž300ããªãªã¹ã¢
ã«ïŒïŒ¬ã®çŽ93ïŒ ãäŸçµŠãããå°¿çŽ ã¯æšæºçã«ã¯ã
ãã®æµžéåã®çŽ1.3ïŒ ãäŸçµŠãããä»ã®æåã®1.8
ïŒ ã°ã«ã³ãŒã¹ã ãã浞é床調ç¯ã®å åã§ããã åŸã€ãŠç匵æ§ãç¶æããããã®æ°Žéã®æµžé床調
ç¯ã¯æžã«ããããã³æ°Žã®ååžåã調ç¯ããããã
ã³ã®æãæ«ç«¯éšåã§ã®æå©å°¿ãã«ã¢ã³ã®äœçšã«ã
ãã塩調ç¯ã«å¯ŸããŠé£æãããããè èã¯ãããª
ãŠã ä¿åãæ倧ã«ããããã«äœãããŠããããã«
èŠããã塩調ç¯ãã«ã¢ã³ã«å¯Ÿããç 究ãç¶ããŠã
ãããè èã®å ¬ç¥ã®â掻æ§âãããªãŠã ååžåæ©
æ§ã ãããæ°ŽçŽ ã€ãªã³ã®æå¹æ§ããã³ïŒãŸãã¯ã
ããã³ã暪åããããªãŠã ãšã®äº€æã®ããã®ã«ãª
ãŠã ã®ã¢ã«ãã¹ããã³èª¿ç¯æå¹æ§ãå å«ãããã
ãååžåããããªãŠã å©å°¿ãŸãã¯å¡©åææ³å©å°¿å€
ã®äœçšã«ãã€ãŠæžå°ããªããªãã°ããããªãŠã ã
æ°Žã®æåºãå¢å€§ããããã®æ段ãšã¯ãã€ãã«ãªã
ãªãã ããåç平衡æ©æ§ããããããããªãŠã ãã³ã
ãŸãã¯çŽ°èèã«å ±éã®ãããªãŠã âã«ãªãŠã âã
ã°ãã·ãŠã äŸåã®ATPâaseæ©æ§ã¯äž»ãšããŠçŽ°è
å€ç©ºéãžã®æµäœéãŸãã¯å šçŽ°èããã³çŽ°èå€å®¹é
ã®çŽ25ïŒ ã§ãããªãŠã ã®æµžé調ç¯å¹æãäžããã
ãã«åããåŸã€ãŠãããªãŠã ä¿æã«ããã極ããŠ
å°éã®å¢å ã¯çŽ°èå€å®¹éãæ¡åŒµããããšãã§ãã
åŸã€ãŠçŽ°è容éãå®è³ªçã«æããåãããšãªãè¡
å§ããã³ç³žçäœéçãå¢å ããããšãã§ããã ä»æ¹ãäžåäœåŸèã®çŽ°èã«ããæžã®æµžé床調ç¯
ã¯å°¿çŽ æ¿åºŠã«ããææã§ã¯ãªããAPHãæ°Žååž
åã«åœ±é¿ããããã«è èã«ãã€ãŠå°¿çŽ éæ¡æ£ãå€
åãããéã«æšæºçã«ã¯ïŒæ¥åœãå°¿çŽ çŽ25ïœãæ
åºããããã®è èã®äžã§ç©è³ªã¯æ°Žã®æåºã®äž»èŠãª
浞é調ç¯ãšããŠåãã å°¿çŽ ã®è¡æŒ¿æ¿åºŠã¯äž¡æ¹ã®èçœè³ªæåéã«ãã€ãŠ
ããã³ç³žçäœã«ããéãããéã®äžéšã®è 现管
ååžåã«ãã€ãŠåœ±é¿ããããšãã§ãããåŸã€ãŠé«
èçœè³ªã®é£é€ã¯å°¿çŽ ããã³æ°Žã®æåºã®äž¡æ¹ãå¢å
ãããäœèçœè³ªæåéãŸãã¯äœäžãã糞çäœé
çã¯å°¿çŽ ããã³æµäœæåºéãæžå°ãããè¿äŒŒãšã
ãŠãã糞çäœéçãæšæºã®ååã«äœäžãããªã
ã°ãå°¿çŽ ã®è¡æŒ¿æ°Žæ¿åºŠã¯äžå®ã®èçœè³ªæåéã§ïŒ
åã«ãªãããã®çµæã¯çŽ°èå 容é䞊ã³ã«çŽ°èå€ã
45ïŒ25ãŸãã¯1.8ã®æ¯çã§æ¡åŒµããäžå®ã®æµžéå§
ããšãã°é¢ä¿æ§ã¯äºç©ºéã«ååšãããäºç©ºéã®ã
ã®éèŠãªå·®ç°ã«å¯Ÿããçç±ã¯ãããªãŠã ãå®è³ªç
ã«çŽ°èå€ç©ºéã«éå®ãããäžæ¹ãå°¿çŽ ã¯å¹Ÿååç
ã«äœæ°Žäžã«åé ãããããšã§ãããåŸã€ãŠå°¿çŽ è¡
挿æ¿åºŠãæ£åžžã®äºåã§ããã现èå€å®¹éãæ¡åŒµã
ãæ£è ã¯å°¿çŽ ã¬ãã«ãæ£åžžã§ããå Žåããããã«
å€éã®æ¡åŒµããå šå®¹éãéæ¬ãããå¢å ããå šé
ããããªãéèŠã§ããããšãã§ããããšã¯å¢å ã
ãâ现èå âæµäœã现èããããã®èããããã®
æ§é ã®åºç»åïŒcompartmentalizationïŒå ã«å
é ããããšããããšã§ããã å¡©ã®ããã«å°¿çŽ ã¯ããç匵æ§ãç¶æããããã«
ååãªæ°Žãšãšãã«æäžããããªãã°æ£åžžãªè¢«æ€è
ã«æ¿ããæ¯æ§ã¯ãªããããããªããé¡èãªå€å°¿æ¯
çã«å¯Ÿãã調æŽã¯äœã®æµäœãäœãããªãŠã è¡çã
äœã«ãªãŠã è¡çã®ã²ã©ãäžå¹³è¡¡ãå å«ããããã«
äºæãããã°ã¢ããžã³å¡©åºã®æ¯æ§ã«äŒŒãŠããç©è³ª
ã®ä¿æã¯å°¿æ¯çã®å šäœã§ãããå€åãåŸãèšåºå
ã«å¯äžãããšèããããšãã§ããã åè¿°ã®å°¿çŽ ããã³å¡©ãšã®é¢ä¿æ§ãèæ ®ããŠãå¡©
åææ³å©å°¿æ²»çãå€å°¿æ¯çã®ãªãæµäœä¿æã®åå
ãªã³ã³ãããŒã«ã§ãããšããããšã§ãããäžæã
ãå°¿çŽ è¡æŒ¿æ¿åºŠãæµäœä¿æãŸãã¯ãã¢ãžãæäžã«
察å¿ããé«è¡å§çãšå ±ã«ååšããå Žåããã®æå¢
å ããå°¿çŽ æåºãèªå°ããããšã¯âãã®è¡æ¶²ã¬ã
ã«ãäœäžãããããšã¯åççã§ããããã«æãã
ãã å¿èè¡ç®¡è çŸæ£ã®å¢å ããå°¿çŽ è¡æ¶²ã¬ãã«ã¯è©
䟡ããããããããã«æ®éã§ãããå¢å ããå°¿çŽ
ã®æµãã¯å°¿çŽ æåºãå¢å ããããå©å°¿å€ããã³ã¢
ãã¬ããªã³é®æå€ã¯å°¿çŽ è¡æ¶²ã¬ãã«ãããã«å¢å
ãããããã§ãããå¡©ããã³å°¿çŽ ä¿æã®ãã®ææ¡
ããçžäºã®é¢ä¿æ§ãèæ ®ããŠé«è¡å§çã®å¡©åææ³
å©å°¿æ²»çã¯åççãªæ²»çæ¹æ³âå¡©åææ³âå€å°¿æ¯
䜵çšæ²»çã®ååã ããæå³ãããããæ æ¬çºæã«
ããã°æ¬æ现æžäžã«èšèŒãããã©ãžã³é žèªå°äœã®
䜿çšãé»è§£è³ªããã³æ°Žå¹³è¡¡å³ã¡ãåç平衡ã®ããª
ãçŽæ¥çãªå¶åŸ¡ãå¯èœã«ããããããŠçµç¹æµäœäžŠ
ã³ã«çŽ°èå€æµäœã®çŽæ¥èª¿æŽãäŸããããšã«ãã€ãŠ
æ¬çºæã®æ²»çã®å¹çšãæ¡å€§ãããæ¬çºæã¯æµžé床
調ç¯ã«ãã€ãŠé»è§£è³ªããã³æ°Žå¹³è¡¡ã®åŠçã«æ³šç®ã
ãæ°èŠãªãããŠçºå±ãããæ¹æ³ãæäŸããã åŸã€ãŠæ¬çºæã¯é«è¡å§çã®æ²»çãé žâå¡©åºå¹³è¡¡
ã劚害ãããå±éºããªãæµäœã®çµç¹æ»æºã®è»œæžã«
察ããè¡åŸåŠçãææã®éæãå¿ èŠãšãããŸãã¯
å¿ èŠãšããªãæ¥æ§ãŸãã¯æ ¢æ§å€å°¿æ¯çã®åŠçãã
ã³èºåèæµ®è «ã®æ²»çã®æç¶æ²»çã«å¯ŸããŠæäŸã
ãã 次ã«å®æœäŸã¯å¡©åææ³å€ããã€ããã¯ãããã¢
ãžãã®ååšãŸãã¯äžåšã§ãããŠã¢ããã©ã€ãã®ã
ã«ãªãé¡äŒŒäœã«ãã€ãŠäŸç€ºãããä»ã®ãã©ãžã³é ž
ååç©ãšå¯Ÿæ¯ããŠæ¬çºæã§å©çšãããã©ãžã³é žèª
å°äœã®å€å°¿äœçšãå ·äœçã«ç€ºãããã«åœ¹ç«ã€ãã®
ã§ããã å®æœäŸ ïŒ é£ç©ããã³æ°Žãéã®ãã«ããã¢ã³ã³ãŒãããŠã³
ãã«äžæ©äžããã«ããããïŒåã®ç¶æéè€20åã³
ã³ãããŒã«ã¯ãªã¢ã©ã³ã¹æéã®æåãå§ãŸã20å
åã«ã¯ã¬ã¢ããã³ïŒïœãç®äžã«äžããããã®åŸçŽ
ã¡ã«æ³šå ¥é床3.0mgïŒKgïŒïœãç¶æããã®ã«åå
ãªè©Šéšååç©ãå«æãã260mOsmïŒïŒ¬ãã³ãã
ãŒã«âPO4ç·©è¡æ¶²ã®1.0mlïŒåéèå 泚å°ãïŒé
èå ã«æ³šå ¥ãã2.0mgïŒKgåç¬æçšéãå ããŠïŒ
å§ããå®éšäžç¶ããã10ååŸããã«ã¯ã¬ã¢ããã³
1.0ïœãç®äžæ³šå°ãããã¯ã¬ã¢ããã³ã¯ãªã¢ã©ã³
ã¹ã糞çäœéé床ã®æž¬å®ã«äœ¿çšããã éèå 泚å°ãå§ããŠ20ååŸãé£ç¶ïŒåã®20åã¯
ãªã¢ã©ã³ã¹ã®æåã次ã®ïŒæéã«ããã€ãŠå®æœã
ããè¡æŒ¿ããã³å°¿æšæ¬ãå°¿çŽ ãæã å°¿é žããããª
ãŠã ãã¯ãã©ã€ããã«ãªãŠã ãã¯ã¬ã¢ããã³ãã
ã³å°¿çŽ ãå å«ããPHããã³æµåé床ã«å¯ŸããŠåæ
ããã ãã©ãžãã€ã«ã°ã¢ããžã³ã¯å°¿çŽ ã®æŽ»æ§ååžåã
é»å®³ãããã«ããã¢ã³ã®å°¿çŽ è¡æŒ¿æ¿åºŠãäœäžãã
ããè¡šãå°¿çŽ è¡æŒ¿æ¿åºŠãäœäžãããå°¿çŽ ããã
ãªãŠã ããã³ã«ãªãŠã ã®æåºãå¢å ãããããã¯
ãã©ã€ãã®æåºã®å¹æã¯å¯å€çã§ãã€ããå°¿é žæ
åºã¯åœ±é¿ãåããªãã€ãã ïŒâã¢ãããã©ãžãã€ã«ã°ã¢ããžã³ããã©ãžã
ã€ã«ã°ã¢ããžã³ã«å¯Ÿããã®ãšåããããã³ãŒã«ã«
åŸã€ãŠãã«ããã¢ã³ã«æäžããå Žåãå°¿çŽ ã¯ãªã¢
ã©ã³ã¹æ¯çããã³è¡æ¶²ã¬ãã«ã®çµæïŒè¡šïŒã¯ã
ã©ãžãã€ã«ã°ã¢ããžã³ïŒè¡šïŒã«å¯Ÿãããããã
ãã«äœããã®ã§ãã€ããäºã€ã®ååç©ã®ãããªãŠ
ã å©å°¿å¹æã¯åæ§ã§ãã€ããããã©ãžãã€ã«ã°ã¢
ããžã³ã¯ã«ãªãŠã å©å°¿å¹æã®æ¹ã倧ããã€ããã¯
ãã©ã€ãã§ã¯æ°å¹ã®ã€ãã«ããã«å€åããããé
ã«å°¿ã®PHã«é¢é£ããã è¡šã«ç€ºãããããã«ã¢ããã©ã€ãã®ãã«ãšã
é¡äŒŒäœã¯ãã«ããã¢ã³ã®å°¿çŽ ã®å°¿çŽ°ç®¡åæ³ãéåžž
ã«äœäžããããå¹æã¯çŽã¡ã«ã§ãããå°¿äžã®å°¿çŽ
æ¿åºŠã確å®ã§ããªãã»ã©äœãç¹ã«é²è¡ãããå°¿çŽ
è¡æŒ¿æ¿åºŠã¯ãã®æåºãäœäžããã«ã€ããŠå®è³ªçã«
å¢å ããã管è ãžã®æŽ»æ§å°¿çŽ åæ³ã®é»å®³ã¯ããã
ã®çµæã®èµ·ããããªè§£éã«æãããããã«ããã¢
ã³ã®ã¢ããã©ã€ãã®ãã«ãªãé¡äŒŒäœã®å®éšã¯å°¿çŽ
æµãçŽ2.0mlïŒåãç¶æããããã«ïŒmlïŒåã«ã
ããŠååãªãã³ãããŒã«éèå 泚å°ïŒ10ïŒ ïŒæº¶æ¶²
ã®ååšäžã§ç¹°ãè¿ããããã®å°¿ã®æµãã¯å°¿çŽ éæ¡
æ£ãæå°ã«ããã®ã«ååã§ãã€ãã éæ¡æ£ãæå°ã«ããããã«çŽ2.0mlïŒåã«å°¿ã®
æµããç¶æããå Žåã¢ããã©ã€ãã®ãã«ãªãé¡äŒŒ
äœã¯ã³ã³ãããŒã«å€ã®åå以äžã«å°¿çŽ ã¯ãªã¢ã©ã³
ã¹ãäœäžããè¡šãããŠå°¿çŽ è¡æŒ¿æ¿åºŠãå¢å€§ã
ãã糞çäœéé床ã¯äžå®ã®ãŸãŸã§ããããå°¿é ž
ã¯ãªã¢ã©ã³ã¹ã¯ã³ã³ãããŒã«å€ã®åå以äžã«åå
ç©ã«ãã€ãŠäœäžãããã®è¡æŒ¿æ¿åºŠã¯ãããã«å¢å€§
ããããããªãŠã ããã³ã¯ãã©ã€ãæåºã¯ã«ãªãŠ
ã ããå¢å ããã äžèšã«èšèŒããããŒã¿ã¯ä»¥äžã®è¡šâã«ç€ºã
ããã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
å®éã«è¡ãªã€ã次ã®å®æœäŸã¯å¡©åææ³å€ããã€
ããã¯ãããã¢ãžãã®ååšããã³äžåšäžã§ãã©ãž
ã³é žèªå°äœã®å€å°¿äœçšãå ·äœçã«ç€ºãããã«åœ¹ç«
ã€ãã®ã§ããã å®æœäŸ ïŒ è¡šããã³ã«ã€ãã«ãããŠãŸããã©ãžãã€ã«
ã°ã¢ããžã³æ¬¡ã«ãã©ãžãã€ã«ã°ã¢ããžã³ãšãã€ã
ãã¯ãããã¢ãžãã®äž¡æ¹ã®å¹æïŒè¡šïŒããã³ä»
æ¹ããã€ããã¯ãããã¢ãžã次ã«ãã€ããã¯ãã
ãã¢ãžãããã³ãã©ãžãã€ã«ã°ã¢ããžã³ã®å¹æã
å°¿çŽ ããã³ç¡æ©é»è§£è³ªã®æåºã«é¢ããŠïŒè¡šïŒç€º
ãããéè€ã³ã³ãããŒã«20åã¯ãªã¢ã©ã³ã¹ã®åã«
ã¯ã¬ã¢ããã³ãç®äžæ³šå°ããç匵ãã³ãããŒã«â
PO4ç·©è¡æ¶²éèå 泚å°ãå§ããïŒmlïŒåã§å®éšäž
ç¶ããã第äºã³ã³ãããŒã«ã¯ãªã¢ã©ã³ã¹åŸçŽã¡ã«
ãã©ãžãã€ã«ã°ã¢ããžã³ãïŒmgïŒKgïŒïœãšïŒmgïŒ
Kgéèå 泚å°ã§éèå ã«æ·»å ããããããã¯ãã€
ããã¯ãããã¢ãžãã1.5mgïŒKgïŒïœãšïŒmgïŒKg
æ³šå ¥ã®é床ã§æ·»å ããããããã®å Žåã«ãã30å
åŸé£ç¶ïŒåã®20åã¯ãªã¢ã©ã³ã¹ãè¡ãªã€ãããã®
åŸçŽã¡ã«ãã³ãããŒã«æ³šå ¥ãæåã®è¬å€çžã«å¯Ÿã
ãŠæ现ã«ç€ºããçšéã§ãã©ãžãã€ã«ã°ã¢ããžã³ã
ãã³ãã€ããã¯ãããã¢ãžãã®äž¡æ¹ãå«æããã
ã®ã«å€ããã30ååŸïŒåããã«20åã¯ãªã¢ã©ã³ã¹
ãè¡ãªã€ããè¡æ¶²ããã³å°¿ãéäŸã®åæã«å§ã
ãã è¡šããã³ã®æåã®è¬å€çžãæ¯èŒãããªã
ã°ãäºã€ã®ååç©ã®å žåçãªå¹æãæçœã§ããã
ãã©ãžãã€ã«ã°ã¢ããžã³ã¯å°¿çŽ æåºãå¢å ããå¢
å ããå°¿æµãã«äžé£ãåããªè¡æŒ¿æ¿åºŠãäœäžãã
ãããããªãŠã ãã«ãªãŠã ããã³ã¯ãã©ã€ãæåº
ãå¢å ãããããããªãŠã ãã«ãªãŠã ãã¯ãã©ã€
ãããã³æµžéæ§æåºã®å¹æã¯ãã©ãžãã€ã«ã°ã¢ã
ãžã³ã®ããã®çŽïŒåã§ãã€ããå°¿çŽ ãã©ã¡ãŒã¿ãŒ
ã«é¢ãããã€ããã¯ãããã¢ãžãã®ããããéç
ã®å¹æã¯å€éã®å¡©åææ³ã«ç±æ¥ããå°¿æµãã®å¢å
ã®ããã§ããã äºã€ã®ååç©ã第äºè¬å€çžã§äœµçšããå Žåãã
ã®å¹æã®åã¯è¡šããã³ã®äž¡æ¹ã«æçœã§ããã
å°¿çŽ ã«é¢ããå¹æã¯å€éã®å©å°¿ãšãã©ãžãã€ã«ã°
ã¢ããžã³ã«ãã€ãŠå¹Ÿåå¢å€§ããååç©ã¯ãããªãŠ
ã ãã¯ãã©ã€ããã«ãªãŠã ããã³æµžéæ§æåºéã
ãã³å°¿æµããå¢å ãããããã«æ··åããã äžèšã§æ€èšããããŒã¿ã以äžã®è¡šããã³ã«
瀺ããã
ããã¯ãããã¢ãžãã®ååšããã³äžåšäžã§ãã©ãž
ã³é žèªå°äœã®å€å°¿äœçšãå ·äœçã«ç€ºãããã«åœ¹ç«
ã€ãã®ã§ããã å®æœäŸ ïŒ è¡šããã³ã«ã€ãã«ãããŠãŸããã©ãžãã€ã«
ã°ã¢ããžã³æ¬¡ã«ãã©ãžãã€ã«ã°ã¢ããžã³ãšãã€ã
ãã¯ãããã¢ãžãã®äž¡æ¹ã®å¹æïŒè¡šïŒããã³ä»
æ¹ããã€ããã¯ãããã¢ãžã次ã«ãã€ããã¯ãã
ãã¢ãžãããã³ãã©ãžãã€ã«ã°ã¢ããžã³ã®å¹æã
å°¿çŽ ããã³ç¡æ©é»è§£è³ªã®æåºã«é¢ããŠïŒè¡šïŒç€º
ãããéè€ã³ã³ãããŒã«20åã¯ãªã¢ã©ã³ã¹ã®åã«
ã¯ã¬ã¢ããã³ãç®äžæ³šå°ããç匵ãã³ãããŒã«â
PO4ç·©è¡æ¶²éèå 泚å°ãå§ããïŒmlïŒåã§å®éšäž
ç¶ããã第äºã³ã³ãããŒã«ã¯ãªã¢ã©ã³ã¹åŸçŽã¡ã«
ãã©ãžãã€ã«ã°ã¢ããžã³ãïŒmgïŒKgïŒïœãšïŒmgïŒ
Kgéèå 泚å°ã§éèå ã«æ·»å ããããããã¯ãã€
ããã¯ãããã¢ãžãã1.5mgïŒKgïŒïœãšïŒmgïŒKg
æ³šå ¥ã®é床ã§æ·»å ããããããã®å Žåã«ãã30å
åŸé£ç¶ïŒåã®20åã¯ãªã¢ã©ã³ã¹ãè¡ãªã€ãããã®
åŸçŽã¡ã«ãã³ãããŒã«æ³šå ¥ãæåã®è¬å€çžã«å¯Ÿã
ãŠæ现ã«ç€ºããçšéã§ãã©ãžãã€ã«ã°ã¢ããžã³ã
ãã³ãã€ããã¯ãããã¢ãžãã®äž¡æ¹ãå«æããã
ã®ã«å€ããã30ååŸïŒåããã«20åã¯ãªã¢ã©ã³ã¹
ãè¡ãªã€ããè¡æ¶²ããã³å°¿ãéäŸã®åæã«å§ã
ãã è¡šããã³ã®æåã®è¬å€çžãæ¯èŒãããªã
ã°ãäºã€ã®ååç©ã®å žåçãªå¹æãæçœã§ããã
ãã©ãžãã€ã«ã°ã¢ããžã³ã¯å°¿çŽ æåºãå¢å ããå¢
å ããå°¿æµãã«äžé£ãåããªè¡æŒ¿æ¿åºŠãäœäžãã
ãããããªãŠã ãã«ãªãŠã ããã³ã¯ãã©ã€ãæåº
ãå¢å ãããããããªãŠã ãã«ãªãŠã ãã¯ãã©ã€
ãããã³æµžéæ§æåºã®å¹æã¯ãã©ãžãã€ã«ã°ã¢ã
ãžã³ã®ããã®çŽïŒåã§ãã€ããå°¿çŽ ãã©ã¡ãŒã¿ãŒ
ã«é¢ãããã€ããã¯ãããã¢ãžãã®ããããéç
ã®å¹æã¯å€éã®å¡©åææ³ã«ç±æ¥ããå°¿æµãã®å¢å
ã®ããã§ããã äºã€ã®ååç©ã第äºè¬å€çžã§äœµçšããå Žåãã
ã®å¹æã®åã¯è¡šããã³ã®äž¡æ¹ã«æçœã§ããã
å°¿çŽ ã«é¢ããå¹æã¯å€éã®å©å°¿ãšãã©ãžãã€ã«ã°
ã¢ããžã³ã«ãã€ãŠå¹Ÿåå¢å€§ããååç©ã¯ãããªãŠ
ã ãã¯ãã©ã€ããã«ãªãŠã ããã³æµžéæ§æåºéã
ãã³å°¿æµããå¢å ãããããã«æ··åããã äžèšã§æ€èšããããŒã¿ã以äžã®è¡šããã³ã«
瀺ããã
ãè¡šã
ãè¡šã
æ¬çºæã§å©çšãããã©ãžã³é
žèªå°äœã¯äŸãã°ç±³
åœç¹èš±ç¬¬3313813å·ã«èšèŒããããããªéåžžã«ã
ãç¥ãããæäœã«åŸã€ãŠè£œé ããããšãã§ããã
åœç¹èš±ç¬¬3313813å·ã«èšèŒããããããªéåžžã«ã
ãç¥ãããæäœã«åŸã€ãŠè£œé ããããšãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ å»è¬çã«äœ¿çšãåŸãæ äœããã³åŒïŒ ãåŒäž ã¯ïŒ¯ãŸãã¯NHã§ããã ã¯NHCONR4R5ãŸãã¯ïŒ®ïŒïŒ£ïŒNR4R5ïŒ2 ïŒåŒäžR4ããã³R5ã¯åã æ°ŽçŽ ãçŽéãŸãã¯å
æéC1-10ã¢ã«ãã«ãã¢ãªãŒã«C1-4ã¢ã«ãã«ã眮
æåºããã«ãªããã¯ãããããã¢ããšãŒããŸãã¯
çŽéãŸãã¯åæéC1-10ã¢ã«ãã«ã§ããã¢ããŸã
ã¯ãžçœ®æã¢ãªãŒã«C1-4ã¢ã«ãã«ãããªã矀ããéž
æããããïŒã§ããã R1ããã³R2ã¯åã æ°ŽçŽ ãã¢ããããã³çœ®æåº
ãçŽéãŸãã¯åæéC1-10ã¢ã«ãã«ãŸãã¯C3-8ã·
ã¯ãã¢ã«ãã«ã§ããã¢ããŸãã¯çœ®æã¢ãããããª
ã矀ããéžæãããããã ãR1ããã³R2ã¯äž¡æ¹
ãã¢ãããŸãã¯çœ®æã¢ããã§ããããšãã§ããªã
ããã³ R3ã¯æ°ŽçŽ ããã«ãªããã¯ãããããã¢ãŸãã¯
ãšãŒãã§ãããã ãæããååç©ããã³ãã®å»è¬çã«äœ¿çšãåŸãå¡©
ãããªãããšãç¹åŸŽãšããåäœçšé圢æ ã®é«è¡å§
æ²»ççšå»è¬çµæç©ã ïŒ åŒã®ååç©ããã©ãžãã€ã«ã°ã¢ããžã³ã§ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ åŒã®ååç©ãïŒâã¢ãããã©ãžãã€ã«ã°ã¢
ããžã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæ
ç©ã ïŒ å»è¬çã«äœ¿çšãåŸãæ äœããã³ (a) åŒïŒ ãåŒäž ã¯ïŒ¯ãŸãã¯NHã§ããã ã¯NHCONR4R5ãŸãã¯ïŒ®ïŒïŒ£ïŒNR4R5ïŒ2 ïŒåŒäžR4ããã³R5ã¯åã æ°ŽçŽ ãçŽéãŸãã¯
åæéC1-10ã¢ã«ãã«ãã¢ãªãŒã«C1-4ã¢ã«ãã«ã
眮æåºããã«ãªããã¯ãããããã¢ããšãŒããŸ
ãã¯çŽéãŸãã¯åæéC1-10ã¢ã«ãã«ã§ããã¢
ããŸãã¯ãžçœ®æã¢ãªãŒã«C1-4ã¢ã«ãã«ãããªã
矀ããéžæããããïŒã§ããã R1ããã³R2ã¯åã æ°ŽçŽ ãã¢ããããã³çœ®æ
åºãçŽéãŸãã¯åæéC1-10ã¢ã«ãã«ãŸãã¯
C3-8ã·ã¯ãã¢ã«ãã«ã§ããã¢ããŸãã¯ãžçœ®æã¢
ãããããªã矀ããéžæãããããã ãR1ã
ãã³R2ã¯äž¡æ¹ãã¢ãããŸãã¯çœ®æã¢ããã§ã
ãããšãã§ããªãããã³ R3ã¯æ°ŽçŽ ããã«ãªããã¯ãããããã¢ãŸã
ã¯ãšãŒãã§ãããã ãæããååç©ããã³ãã®å»è¬çã«äœ¿çšãåŸã
å¡©ããã³ (b) å®è³ªçã«ãšã¿ã¯ãªããã¯ã¢ã·ãããããã»ã
ãããã¡ã¿ãããã ãŸãªãã³ãã¯ãããã¢ãžã
ããã³ãããã¯ãããã¢ãžããå å«ãããã³ãŸ
ãã¢ãžã¢ãžã³ãã¯ããã¿ãªãã³ãããã¿ãŸã³ã
ã¡ãã©ãŸã³ãã€ã³ãã¯ãªãã³ãã¢ã»ã¿ãŸãŒã«ã¢
ããããšããã·ãŸãŒã«ã¢ããããã³ã¡ã¿ãŸã«ã¢
ãããããªã矀ããéžæãããå¡©åææ³å€ã®æ··
åç©ãããªãããšãç¹åŸŽãšããåäœçšé圢æ ã®
é«è¡å§æ²»ççšå»è¬çµæç©ã ïŒ åŒã®ååç©ããã©ãŸã€ã«ã°ã¢ããžã³ã§ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ å¡©åææ³å€ããããã¯ãããã¢ãžãã§ããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33673682A | 1982-01-04 | 1982-01-04 | |
| US06/336,735 US4594349A (en) | 1982-01-04 | 1982-01-04 | Hyperuretic agents |
| US336736 | 1982-01-04 | ||
| US336735 | 1982-01-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58150510A JPS58150510A (ja) | 1983-09-07 |
| JPH0557242B2 true JPH0557242B2 (ja) | 1993-08-23 |
Family
ID=26990347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57234891A Granted JPS58150510A (ja) | 1982-01-04 | 1982-12-29 | å€å°¿å€ |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0083779B1 (ja) |
| JP (1) | JPS58150510A (ja) |
| AT (1) | ATE24997T1 (ja) |
| AU (1) | AU564588B2 (ja) |
| CA (1) | CA1183456A (ja) |
| DE (1) | DE3275160D1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| DE19600721A1 (de) * | 1996-01-12 | 1997-07-17 | Hoechst Ag | Verwendung von Inhibitoren des Carboanhydratase (CAH) zum Herstellen eines Medikaments zur Behandlung von Krebs |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3268406A (en) * | 1961-10-12 | 1966-08-23 | Merck & Co Inc | Compositions and method of using (3-amino-pyrazinoyl) guanidines |
| US3240780A (en) * | 1963-12-23 | 1966-03-15 | Merck & Co Inc | Amino-pyrazinoyl guanidines |
| US3575975A (en) * | 1968-07-25 | 1971-04-20 | Merck & Co Inc | Process for the preparation of 3-aminopyrazinoylureas |
| NL7600500A (nl) * | 1975-02-03 | 1976-08-05 | Merck & Co Inc | Werkwijze voor het bereiden van farmaceutische preparaten. |
| AU522049B2 (en) * | 1978-01-13 | 1982-05-13 | Van Scott, Eugene Joseph | Treatment of psoriasis |
-
1982
- 1982-12-22 DE DE8282111893T patent/DE3275160D1/de not_active Expired
- 1982-12-22 AT AT82111893T patent/ATE24997T1/de not_active IP Right Cessation
- 1982-12-22 EP EP82111893A patent/EP0083779B1/en not_active Expired
- 1982-12-23 CA CA000418427A patent/CA1183456A/en not_active Expired
- 1982-12-24 AU AU91906/82A patent/AU564588B2/en not_active Ceased
- 1982-12-29 JP JP57234891A patent/JPS58150510A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| AU9190682A (en) | 1983-07-14 |
| EP0083779A1 (en) | 1983-07-20 |
| ATE24997T1 (de) | 1987-02-15 |
| EP0083779B1 (en) | 1987-01-21 |
| JPS58150510A (ja) | 1983-09-07 |
| AU564588B2 (en) | 1987-08-20 |
| DE3275160D1 (en) | 1987-02-26 |
| CA1183456A (en) | 1985-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Perkins et al. | Renal and cardiac lesions in potassium deficiency due to chronic diarrhea | |
| EP1696932B1 (en) | Use of treprostinil to improve kidney functions | |
| KR100879559B1 (ko) | 믞í ìœë늬ì ì¥ì ì ì¹ë£ ëë ìë°©ì© ì ìœì¡°ì±ë¬Œ | |
| JP3699124B2 (ja) | ã¿ã€ãïœïœç³å°¿ç ã®ãã³ãªã³é žã¯ãã é«çšéæ²»ç | |
| CN1309552A (zh) | å«ææµ·æ°Žçè¯ç©ãä¿å¥å/æååŠç»åç©åå ¶åºçš | |
| US5547942A (en) | Method of treatment of diabetes mellitus by administration of adenosine 5'-t | |
| JPH082789B2 (ja) | ã¿ã¢ãã·ããšã³åã¯ãã®è£œè¬äžèªå®¹æ§å¡©ãå«æãã也ç¬ã®æ²»çå€ | |
| US4663322A (en) | Antihypertensive hyperuretic and saluretic agent combinations | |
| JP2840089B2 (ja) | åºä¹³åç©ã®è¡æž ããªã°ãªã»ãªããã³ã¬ã¹ãããŒã«æ°Žæºã®èª¿ç¯ãéäžæ¹æ³ | |
| Harry et al. | Efficacy of 4-methylpyrazole in ethylene glycol poisoning: clinical and toxicokinetic aspects | |
| US4952582A (en) | Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents | |
| US4594349A (en) | Hyperuretic agents | |
| EP0150063A2 (en) | Therapeutic and/or preventive ophthalmic solution for intraocular hypertension and glaucoma | |
| JPH0372463A (ja) | è æ©èœæ¹åå€ | |
| KR20060004959A (ko) | ì ì¥ êž°ë¥ ì í륌 ê°ë ê°ë³ ëììì ìŽëš ìì© ê°ì ë°©ë² | |
| JPH0557242B2 (ja) | ||
| Murase et al. | Synergistic effects of nitric oxide and prostaglandins on renal escape from vasopressin-induced antidiuresis | |
| AU2922389A (en) | Improving toxicity profiles in chemotherapy | |
| Gouvea et al. | Oral administration of L-arginine decreases blood pressure and increases renal excretion of sodium and water in renovascular hypertensive rats | |
| Gillenwater | Antidiuretic properties of chlorothiazide in diabetes insipidus dogs | |
| JPS63501219A (ja) | å åæ³ç³»ãã«ã¢ã³çææå¶çšéçµå£æäžæ²»ççµæç©ããã³æ¹æ³ | |
| EP0286252A2 (en) | Anti-cancer composition & method featuring cyanine dyes | |
| JPH11515014A (ja) | åºä¹³é¡ã®æŠæ¥ãªãºã ã®èª¿æŽæ¹æ³ | |
| Clark et al. | Clinical pharmacological studies of Kö 1173--a new antiarrhythmic agent. | |
| EP0140958B1 (en) | Oncolytic drug combinations |